Therapeutic drug monitoring of oral targeted antineoplastic drugs
Purpose This review provides an overview of the current challenges in oral targeted antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug monitoring (TDM). Factors influencing the pharmacokinetic exposure in OAD therapy are depicted together with an overview of diff...
Saved in:
| Published in | European journal of clinical pharmacology Vol. 77; no. 4; pp. 441 - 464 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.04.2021
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Purpose
This review provides an overview of the current challenges in oral targeted antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug monitoring (TDM). Factors influencing the pharmacokinetic exposure in OAD therapy are depicted together with an overview of different TDM approaches. Finally, current evidence for TDM for all approved OADs is reviewed.
Methods
A comprehensive literature search (covering literature published until April 2020), including primary and secondary scientific literature on pharmacokinetics and dose individualisation strategies for OADs, together with US FDA Clinical Pharmacology and Biopharmaceutics Reviews and the Committee for Medicinal Products for Human Use European Public Assessment Reports was conducted.
Results
OADs are highly potent drugs, which have substantially changed treatment options for cancer patients. Nevertheless, high pharmacokinetic variability and low treatment adherence are risk factors for treatment failure. TDM is a powerful tool to individualise drug dosing, ensure drug concentrations within the therapeutic window and increase treatment success rates. After reviewing the literature for 71 approved OADs, we show that exposure-response and/or exposure-toxicity relationships have been established for the majority. Moreover, TDM has been proven to be feasible for individualised dosing of abiraterone, everolimus, imatinib, pazopanib, sunitinib and tamoxifen in prospective studies. There is a lack of experience in how to best implement TDM as part of clinical routine in OAD cancer therapy.
Conclusion
Sub-therapeutic concentrations and severe adverse events are current challenges in OAD treatment, which can both be addressed by the application of TDM-guided dosing, ensuring concentrations within the therapeutic window. |
|---|---|
| AbstractList | Purpose
This review provides an overview of the current challenges in oral targeted antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug monitoring (TDM). Factors influencing the pharmacokinetic exposure in OAD therapy are depicted together with an overview of different TDM approaches. Finally, current evidence for TDM for all approved OADs is reviewed.
Methods
A comprehensive literature search (covering literature published until April 2020), including primary and secondary scientific literature on pharmacokinetics and dose individualisation strategies for OADs, together with US FDA Clinical Pharmacology and Biopharmaceutics Reviews and the Committee for Medicinal Products for Human Use European Public Assessment Reports was conducted.
Results
OADs are highly potent drugs, which have substantially changed treatment options for cancer patients. Nevertheless, high pharmacokinetic variability and low treatment adherence are risk factors for treatment failure. TDM is a powerful tool to individualise drug dosing, ensure drug concentrations within the therapeutic window and increase treatment success rates. After reviewing the literature for 71 approved OADs, we show that exposure-response and/or exposure-toxicity relationships have been established for the majority. Moreover, TDM has been proven to be feasible for individualised dosing of abiraterone, everolimus, imatinib, pazopanib, sunitinib and tamoxifen in prospective studies. There is a lack of experience in how to best implement TDM as part of clinical routine in OAD cancer therapy.
Conclusion
Sub-therapeutic concentrations and severe adverse events are current challenges in OAD treatment, which can both be addressed by the application of TDM-guided dosing, ensuring concentrations within the therapeutic window. This review provides an overview of the current challenges in oral targeted antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug monitoring (TDM). Factors influencing the pharmacokinetic exposure in OAD therapy are depicted together with an overview of different TDM approaches. Finally, current evidence for TDM for all approved OADs is reviewed. A comprehensive literature search (covering literature published until April 2020), including primary and secondary scientific literature on pharmacokinetics and dose individualisation strategies for OADs, together with US FDA Clinical Pharmacology and Biopharmaceutics Reviews and the Committee for Medicinal Products for Human Use European Public Assessment Reports was conducted. OADs are highly potent drugs, which have substantially changed treatment options for cancer patients. Nevertheless, high pharmacokinetic variability and low treatment adherence are risk factors for treatment failure. TDM is a powerful tool to individualise drug dosing, ensure drug concentrations within the therapeutic window and increase treatment success rates. After reviewing the literature for 71 approved OADs, we show that exposure-response and/or exposure-toxicity relationships have been established for the majority. Moreover, TDM has been proven to be feasible for individualised dosing of abiraterone, everolimus, imatinib, pazopanib, sunitinib and tamoxifen in prospective studies. There is a lack of experience in how to best implement TDM as part of clinical routine in OAD cancer therapy. Sub-therapeutic concentrations and severe adverse events are current challenges in OAD treatment, which can both be addressed by the application of TDM-guided dosing, ensuring concentrations within the therapeutic window. This review provides an overview of the current challenges in oral targeted antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug monitoring (TDM). Factors influencing the pharmacokinetic exposure in OAD therapy are depicted together with an overview of different TDM approaches. Finally, current evidence for TDM for all approved OADs is reviewed.PURPOSEThis review provides an overview of the current challenges in oral targeted antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug monitoring (TDM). Factors influencing the pharmacokinetic exposure in OAD therapy are depicted together with an overview of different TDM approaches. Finally, current evidence for TDM for all approved OADs is reviewed.A comprehensive literature search (covering literature published until April 2020), including primary and secondary scientific literature on pharmacokinetics and dose individualisation strategies for OADs, together with US FDA Clinical Pharmacology and Biopharmaceutics Reviews and the Committee for Medicinal Products for Human Use European Public Assessment Reports was conducted.METHODSA comprehensive literature search (covering literature published until April 2020), including primary and secondary scientific literature on pharmacokinetics and dose individualisation strategies for OADs, together with US FDA Clinical Pharmacology and Biopharmaceutics Reviews and the Committee for Medicinal Products for Human Use European Public Assessment Reports was conducted.OADs are highly potent drugs, which have substantially changed treatment options for cancer patients. Nevertheless, high pharmacokinetic variability and low treatment adherence are risk factors for treatment failure. TDM is a powerful tool to individualise drug dosing, ensure drug concentrations within the therapeutic window and increase treatment success rates. After reviewing the literature for 71 approved OADs, we show that exposure-response and/or exposure-toxicity relationships have been established for the majority. Moreover, TDM has been proven to be feasible for individualised dosing of abiraterone, everolimus, imatinib, pazopanib, sunitinib and tamoxifen in prospective studies. There is a lack of experience in how to best implement TDM as part of clinical routine in OAD cancer therapy.RESULTSOADs are highly potent drugs, which have substantially changed treatment options for cancer patients. Nevertheless, high pharmacokinetic variability and low treatment adherence are risk factors for treatment failure. TDM is a powerful tool to individualise drug dosing, ensure drug concentrations within the therapeutic window and increase treatment success rates. After reviewing the literature for 71 approved OADs, we show that exposure-response and/or exposure-toxicity relationships have been established for the majority. Moreover, TDM has been proven to be feasible for individualised dosing of abiraterone, everolimus, imatinib, pazopanib, sunitinib and tamoxifen in prospective studies. There is a lack of experience in how to best implement TDM as part of clinical routine in OAD cancer therapy.Sub-therapeutic concentrations and severe adverse events are current challenges in OAD treatment, which can both be addressed by the application of TDM-guided dosing, ensuring concentrations within the therapeutic window.CONCLUSIONSub-therapeutic concentrations and severe adverse events are current challenges in OAD treatment, which can both be addressed by the application of TDM-guided dosing, ensuring concentrations within the therapeutic window. PurposeThis review provides an overview of the current challenges in oral targeted antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug monitoring (TDM). Factors influencing the pharmacokinetic exposure in OAD therapy are depicted together with an overview of different TDM approaches. Finally, current evidence for TDM for all approved OADs is reviewed.MethodsA comprehensive literature search (covering literature published until April 2020), including primary and secondary scientific literature on pharmacokinetics and dose individualisation strategies for OADs, together with US FDA Clinical Pharmacology and Biopharmaceutics Reviews and the Committee for Medicinal Products for Human Use European Public Assessment Reports was conducted.ResultsOADs are highly potent drugs, which have substantially changed treatment options for cancer patients. Nevertheless, high pharmacokinetic variability and low treatment adherence are risk factors for treatment failure. TDM is a powerful tool to individualise drug dosing, ensure drug concentrations within the therapeutic window and increase treatment success rates. After reviewing the literature for 71 approved OADs, we show that exposure-response and/or exposure-toxicity relationships have been established for the majority. Moreover, TDM has been proven to be feasible for individualised dosing of abiraterone, everolimus, imatinib, pazopanib, sunitinib and tamoxifen in prospective studies. There is a lack of experience in how to best implement TDM as part of clinical routine in OAD cancer therapy.ConclusionSub-therapeutic concentrations and severe adverse events are current challenges in OAD treatment, which can both be addressed by the application of TDM-guided dosing, ensuring concentrations within the therapeutic window. |
| Author | Mueller-Schoell, Anna Scherf-Clavel, Oliver Kloft, Charlotte van Dyk, Madelé Groenland, Stefanie L. Jaehde, Ulrich Huitema, Alwin D.R. Huisinga, Wilhelm Michelet, Robin Steeghs, Neeltje |
| Author_xml | – sequence: 1 givenname: Anna surname: Mueller-Schoell fullname: Mueller-Schoell, Anna organization: Dept. of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Graduate Research Training Program, PharMetrX – sequence: 2 givenname: Stefanie L. surname: Groenland fullname: Groenland, Stefanie L. organization: Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek – sequence: 3 givenname: Oliver surname: Scherf-Clavel fullname: Scherf-Clavel, Oliver organization: Institute of Pharmacy and Food Chemistry, Julius-Maximilians-Universität Würzburg – sequence: 4 givenname: Madelé surname: van Dyk fullname: van Dyk, Madelé organization: College of Medicine and Public Health, Flinders University – sequence: 5 givenname: Wilhelm surname: Huisinga fullname: Huisinga, Wilhelm organization: Institute of Mathematics, University of Potsdam – sequence: 6 givenname: Robin surname: Michelet fullname: Michelet, Robin organization: Dept. of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin – sequence: 7 givenname: Ulrich surname: Jaehde fullname: Jaehde, Ulrich organization: Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn – sequence: 8 givenname: Neeltje surname: Steeghs fullname: Steeghs, Neeltje organization: Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek – sequence: 9 givenname: Alwin D.R. surname: Huitema fullname: Huitema, Alwin D.R. organization: Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek, Department of Clinical Pharmacy, University Medical Center, Utrecht University – sequence: 10 givenname: Charlotte orcidid: 0000-0001-9344-8514 surname: Kloft fullname: Kloft, Charlotte email: charlotte.kloft@fu-berlin.de organization: Dept. of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33165648$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUFvFSEUhYmpsa_VP-DCTOLGzeiFy8zAxqRpbDVp4qauCY-BV5p5MAJj0n8v42urdtEVJHzn5BzOCTkKMVhC3lL4SAGGTxmAMdECgxYQKG_FC7KhHFlLgdMjsgFA2vZygGNykvMtAO0k4CtyjEj7rudiQ86ub2zSs12KN82Yll2zj8GXmHzYNdE1MempKTrtbLFjo0PxwcZ50vmBz6_JS6enbN_cn6fkx8WX6_Ov7dX3y2_nZ1et6TiU1lHH0AmJGiXjuF3vI5fgxIjS4jg4wUxPtyCcYQJ7Nhhgg9xay5kQTuIp-XzwnZft3o7GhlKzqTn5vU53Kmqv_n8J_kbt4i81SOwE76rBh3uDFH8uNhe199nYadK10pIV452QPeeUVfT9E_Q2LinUepWSA_YdH0Sl3v2b6DHKw-9WgB0Ak2LOybpHhIJaJ1SHCVWdUP2ZUK0i8URkfNHFx7WVn56X4kGa53U_m_7Gfkb1Gz0Qr6o |
| CitedBy_id | crossref_primary_10_1007_s12281_023_00474_0 crossref_primary_10_3390_cancers13246281 crossref_primary_10_1097_FTD_0000000000000997 crossref_primary_10_1097_FTD_0000000000001206 crossref_primary_10_3390_pharmaceutics13101708 crossref_primary_10_1515_cclm_2023_0468 crossref_primary_10_3390_molecules28052127 crossref_primary_10_1016_j_jpba_2023_115594 crossref_primary_10_1016_j_prmedi_2024_10_006 crossref_primary_10_3390_pharmaceutics15041222 crossref_primary_10_1007_s11654_023_00486_9 crossref_primary_10_3389_fped_2022_923419 crossref_primary_10_1016_j_bulcan_2023_02_019 crossref_primary_10_1016_j_jpba_2021_114418 crossref_primary_10_1097_FTD_0000000000000905 crossref_primary_10_1248_bpb_b22_00840 crossref_primary_10_1007_s40262_021_01077_z crossref_primary_10_1080_14740338_2021_1965990 crossref_primary_10_3390_cancers14194566 crossref_primary_10_3389_fchem_2023_1191075 crossref_primary_10_3390_ph14020119 crossref_primary_10_31744_einstein_journal_2024AO0693 crossref_primary_10_1097_FTD_0000000000001159 crossref_primary_10_3390_ph14020115 crossref_primary_10_1136_bmjopen_2020_047173 crossref_primary_10_1016_j_therap_2021_12_002 crossref_primary_10_3390_ph16101445 crossref_primary_10_1080_17425255_2021_1943357 crossref_primary_10_3390_ijms251910453 crossref_primary_10_1007_s00280_025_04761_0 crossref_primary_10_1097_FTD_0000000000001151 crossref_primary_10_1007_s40262_023_01293_9 crossref_primary_10_1111_tri_13952 crossref_primary_10_3390_onco4040023 crossref_primary_10_1007_s11030_022_10387_8 crossref_primary_10_3390_ph14060494 crossref_primary_10_1016_j_jchromb_2023_123872 crossref_primary_10_1016_j_jpba_2024_116586 crossref_primary_10_1097_FTD_0000000000000895 crossref_primary_10_1007_s00280_024_04741_w crossref_primary_10_1016_j_jpba_2021_114562 crossref_primary_10_2174_2213337208666210816112837 crossref_primary_10_3390_antibiotics10091110 crossref_primary_10_1007_s40262_023_01266_y crossref_primary_10_1093_jac_dkae103 crossref_primary_10_1159_000530447 crossref_primary_10_2139_ssrn_3927615 crossref_primary_10_3390_cancers16122193 crossref_primary_10_1016_j_clgc_2024_102064 crossref_primary_10_1002_slct_202204181 crossref_primary_10_1248_bpb_b22_00917 crossref_primary_10_5582_ddt_2024_01040 crossref_primary_10_3389_fonc_2021_815040 crossref_primary_10_1097_FTD_0000000000001175 crossref_primary_10_1097_FTD_0000000000001174 crossref_primary_10_1016_j_critrevonc_2024_104385 crossref_primary_10_3390_cancers13246329 crossref_primary_10_3390_pharmaceutics14091844 crossref_primary_10_1038_s41416_024_02585_y crossref_primary_10_3389_fphar_2022_897951 crossref_primary_10_1124_molpharm_122_000539 crossref_primary_10_1248_yakushi_24_00018 crossref_primary_10_1016_j_chroma_2024_464698 crossref_primary_10_3390_ph14100995 crossref_primary_10_1007_s10928_024_09912_z crossref_primary_10_1002_aoc_6629 crossref_primary_10_1177_17588359241250130 crossref_primary_10_1007_s40265_021_01654_3 crossref_primary_10_2217_pgs_2023_0198 crossref_primary_10_1097_FTD_0000000000001245 crossref_primary_10_3389_fonc_2022_1015200 crossref_primary_10_1016_j_jpba_2023_115311 crossref_primary_10_1038_s41598_023_32035_3 crossref_primary_10_1016_j_jpba_2022_115033 crossref_primary_10_1016_S2352_3026_21_00232_5 crossref_primary_10_14712_23362936_2023_16 crossref_primary_10_1007_s40262_023_01260_4 crossref_primary_10_1097_FTD_0000000000001081 crossref_primary_10_1177_17588359241248328 crossref_primary_10_1021_acsapm_4c01231 crossref_primary_10_1097_QCO_0000000000000740 crossref_primary_10_3390_pharmaceutics14061224 crossref_primary_10_3892_etm_2025_12819 crossref_primary_10_1111_ppl_13472 crossref_primary_10_3390_pharmaceutics15041149 crossref_primary_10_1016_j_heliyon_2023_e15963 crossref_primary_10_3390_ph15050614 crossref_primary_10_1016_j_cll_2025_01_014 crossref_primary_10_7759_cureus_32474 crossref_primary_10_1007_s00228_022_03420_0 crossref_primary_10_1556_2068_2021_54_4_3 crossref_primary_10_1007_s00520_024_09136_4 crossref_primary_10_1016_S1877_1203_23_00157_X crossref_primary_10_2174_0118715206290110240326071909 crossref_primary_10_1208_s12248_024_00918_6 crossref_primary_10_3390_molecules27020482 crossref_primary_10_1080_17425255_2024_2353749 crossref_primary_10_1111_jcpt_13517 crossref_primary_10_3390_pharmaceutics14071317 crossref_primary_10_3390_pharmaceutics15071859 crossref_primary_10_1016_j_jchromb_2025_124526 crossref_primary_10_2147_TCRM_S263832 crossref_primary_10_1080_00304948_2023_2239118 crossref_primary_10_1080_17425255_2021_2029403 crossref_primary_10_2215_CJN_0000000000000395 crossref_primary_10_3390_pharmaceutics15092181 crossref_primary_10_1016_j_ejps_2022_106254 crossref_primary_10_1016_j_jchromb_2024_124100 crossref_primary_10_59761_RCR5090 crossref_primary_10_3390_pharmaceutics15051524 crossref_primary_10_1002_prp2_862 crossref_primary_10_1016_j_biopha_2022_113393 crossref_primary_10_21518_ms2023_422 crossref_primary_10_3390_separations9120403 crossref_primary_10_1016_j_jpba_2023_115255 crossref_primary_10_1007_s40262_024_01409_9 crossref_primary_10_1007_s40262_023_01283_x crossref_primary_10_1002_cpt_3193 crossref_primary_10_3390_curroncol30050367 crossref_primary_10_1016_j_cej_2024_149484 crossref_primary_10_1159_000542461 crossref_primary_10_1038_s41563_024_02096_4 crossref_primary_10_3390_cancers15133293 crossref_primary_10_1097_FTD_0000000000001013 crossref_primary_10_1200_PO_22_00538 crossref_primary_10_2174_1573412918666220329110712 crossref_primary_10_1097_FTD_0000000000001097 crossref_primary_10_3389_fpubh_2023_1294126 crossref_primary_10_3389_fonc_2022_821807 crossref_primary_10_1248_bpb_b21_01098 crossref_primary_10_1177_10781552241269738 crossref_primary_10_3389_fonc_2023_1146108 crossref_primary_10_3390_jcm14010145 crossref_primary_10_1002_jhet_4834 crossref_primary_10_1007_s41870_024_02314_x crossref_primary_10_3389_fphar_2022_931495 |
| Cites_doi | 10.2133/dmpk.dmpk-14-rg-031 10.1007/s12032-019-1263-3 10.1016/j.ijantimicag.2014.12.010 10.1038/clpt.2011.174 10.1158/1078-0432.ccr-07-0004 10.1007/s00228-019-02704-2 10.1097/FTD.0000000000000194 10.1200/jco.2008.20.4818 10.1111/bcp.13591 10.1093/annonc/mdv103 10.1038/sj.pcan.4500782 10.1111/j.1365-2125.2005.02335.x 10.1007/s40262-017-0526-4 10.1200/jco.2017.76.4381 10.1200/jco.2012.47.2787 10.2133/dmpk.dmpk-13-rg-126 10.1111/bcp.13901 10.3389/fphar.2019.00530 10.1007/s00280-014-2435-7 10.1038/clpt.2011.153 10.1093/jnci/djp079 10.1038/tpj.2016.60 10.1007/s40262-016-0443-y 10.1158/1078-0432.ccr-15-1470 10.1007/s00228-012-1385-4 10.1016/j.clgc.2015.01.007 10.2165/00003088-199018040-00004 10.1007/s10637-016-0346-7 10.1016/j.clcc.2019.10.004 10.3389/fphar.2020.00283 10.1002/jppr.1432 10.1200/jco.2005.16.584 10.1002/jcph.73 10.1002/ccr3.2191 10.1007/s40262-017-0559-8 10.1016/j.jchromb.2019.01.001 10.1046/j.1472-8206.2002.00086.x 10.1016/s1470-2045(13)70464-9 10.1200/jco.2001.19.13.3267 10.1007/s00280-017-3452-0 10.1007/s00280-012-1998-4 10.1097/ftd.0000000000000195 10.1093/annonc/mdv538 10.1007/s40262-019-00808-7 10.1159/000019526 10.1007/s00280-014-2599-1 10.1002/psp4.12210 10.1007/s40262-016-0404-5 10.1016/s1470-2045(17)30680-0 10.1620/tjem.237.173 10.1056/nejmoa1203421 10.1111/fcp.12327 10.1002/jcph.1520 10.3324/haematol.2011.045666 10.1093/jnci/94.9.652 10.1007/s40262-014-0178-6 10.1097/ftd.0b013e3181b2c8cf 10.1016/j.ejca.2015.12.029 10.1158/1078-0432.ccr-17-2652 10.1038/tpj.2014.34 10.1200/jco.2004.06.075 10.1007/s40262-014-0137-2 10.1007/s11523-014-0349-2 10.1097/ftd.0000000000000767 10.1111/bcp.12907 10.1002/jcph.902 10.1007/s10147-018-1300-9 10.1002/cpt.787 10.1002/jcph.1547 10.1182/blood.V126.23.4172.4172 10.1016/j.ctrv.2009.08.004 10.1007/s10928-018-9600-2 10.1002/cpt.1960 10.1002/cpt.1989 10.1200/jco.2008.26.15_suppl.7064 10.1093/annonc/mdz244.004 10.1200/jco.19.01758 10.1016/j.ctrv.2010.08.006 10.1093/annonc/mdi247 10.1056/nejmoa1001671 10.1016/s1470-2045(13)70240-7 10.1097/ftd.0000000000000004 10.1111/j.1365-2125.2006.02719.x 10.1038/bjc.2014.194 10.1007/s40262-017-0565-x 10.3324/haematol.2018.213157 10.1208/s12248-016-9927-9 10.1002/phar.2339 10.1158/1078-0432.ccr-09-0369 10.1200/jco.2005.02.2194 10.1002/jcph.1556 10.1038/s41391-019-0179-5 10.1158/1078-0432.ccr-16-0536 10.1007/s00280-014-2403-2 10.1111/imj.13412 10.1016/j.ejca.2013.11.022 10.1007/s40262-018-0683-0 10.1038/s41598-019-54804-9 10.1007/s00280-016-2993-y 10.1177/0091270008318006 10.1002/jcph.788 10.1007/s00280-014-2473-1 10.1158/1078-0432.ccr-11-0509 10.1007/s40262-020-00863-5 10.1016/B978-0-12-810477-4.00007-6 10.1016/j.cca.2017.07.012 10.3999/jscpt.43.29 10.1016/j.jpba.2017.07.029 10.1016/j.clgc.2018.12.001 10.4155/ipk-2018-0005 10.1007/s00280-019-04002-1 10.1007/s10147-018-1302-7 10.1111/bcp.13223 10.1007/s40262-016-0452-x 10.1007/s10928-016-9466-0 10.1016/j.clpt.2006.04.007 10.1038/psp.2014.12 10.1182/blood-2007-10-116475 10.1002/jcph.1467 10.1111/j.1365-2125.2005.02372.x 10.1097/ftd.0000000000000349 10.1007/s00228-015-1967-z 10.1016/j.jpba.2009.02.008 10.1158/1078-0432.ccr-12-0490 10.1248/bpb.b17-00521 10.1007/s00216-018-0951-8 10.1007/s00280-015-2862-0 10.1007/s40262-013-0108-z 10.1038/clpt.2010.199 10.1182/blood-2006-07-036012 10.1007/s00228-015-1968-y 10.1007/s00228-015-1846-7 10.1007/s00280-016-3050-6 10.1007/s00228-011-1200-7 10.1016/j.ejca.2018.07.128 10.1002/jcph.102 10.1007/s00280-015-2891-8 10.1016/j.cllc.2014.12.004 10.2147/cpaa.s42796 10.1182/blood-2017-05-786566 10.1248/bpb.b15-00103 10.1007/s12032-010-9541-0 10.1016/j.aca.2018.09.004 10.2217/bmm.15.78 10.2165/00003088-200544020-00002 10.1097/ftd.0000000000000260 10.1016/j.ejca.2016.11.027 10.1007/s40262-016-0461-9 10.1097/ftd.0b013e318292b931 10.1111/j.1349-7006.2009.01237.x 10.1007/s10549-013-2826-1 10.1002/cpt.1338 10.1016/j.steroids.2014.08.007 10.21037/tcr.2017.09.14 10.1016/j.ejca.2020.02.012 10.1038/clpt.2011.32 10.1038/bjc.2014.503 10.1002/bmc.4147 10.1634/theoncologist.2011-0439 10.1007/s10549-015-3562-5 10.1007/s11095-017-2185-4 10.1002/cpt.1515 10.1007/s00280-018-3597-5 10.1038/sj.bjc.6604355 10.2165/0003088-200847120-00005 10.1111/j.1349-7006.2008.00837.x 10.3389/fphar.2020.00794 10.1002/cpt.937 10.1002/jcph.849 10.1002/jcph.218 10.1016/j.oraloncology.2012.03.020 10.1002/jcph.917 10.1007/s40262-016-0391-6 10.1093/annonc/mdv189 10.1007/s11523-015-0375-8 10.1016/j.lungcan.2013.12.001 10.1056/nejmoa1205127 10.1158/1078-0432.ccr-16-1255 10.1016/j.jpba.2019.06.034 10.1016/j.phrs.2017.04.029 10.1007/s00280-018-3579-7 10.1007/s11523-017-0524-3 10.1158/1535-7163.mct-10-0379 10.1007/s00280-009-1170-y 10.1007/s00280-019-03929-9 10.1200/jco.2015.33.7_suppl.506 10.1007/s00228-011-1042-3 10.1007/s40262-017-0571-z 10.1111/j.1742-7843.2009.00533.x 10.1002/jcph.263 10.1111/j.1365-2125.2011.03963.x 10.1200/jco.2012.43.5362 10.1002/jcph.728 10.1097/ftd.0b013e31826aabc3 10.1371/journal.pone.0042875 10.1200/jco.2010.31.4427 10.1007/s40262-018-0714-x 10.1007/s00280-018-3687-4 10.1111/bcp.12378 10.1007/s10928-019-09659-y 10.1111/bcp.13327 10.1093/annonc/mdx372.003 10.1007/s40262-017-0582-9 10.1158/1078-0432.ccr-05-2596 10.1007/s00280-017-3463-x 10.1186/s40780-014-0008-x 10.1007/s00280-014-2617-3 10.1007/s40262-016-0439-7 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020. corrected publication 2020 The Author(s) 2020. corrected publication 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2020, corrected publication 2020 |
| Copyright_xml | – notice: The Author(s) 2020. corrected publication 2020 – notice: The Author(s) 2020. corrected publication 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2020, corrected publication 2020 |
| DBID | C6C AAYXX CITATION NPM 3V. 7RV 7TK 7U9 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s00228-020-03014-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-1041 |
| EndPage | 464 |
| ExternalDocumentID | PMC7935845 33165648 10_1007_s00228_020_03014_8 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: Freie Universität Berlin (1008) – fundername: ; |
| GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 04C 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29G 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3SX 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67N 67Z 6NX 6PF 78A 7RV 7X7 88E 8AO 8FI 8FJ 8FW 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYOK AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFO ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADOJX ADRFC ADTPH ADURQ ADYFF ADYOE ADYPR ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECT EIHBH EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK6 WK8 WOW Y6R YLTOR Z45 Z7U Z7V Z7W Z81 Z82 Z83 Z87 Z8O Z8P Z8Q Z8U Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT NPM 7TK 7U9 7XB 8FK ABRTQ H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c540t-f1f23f893a39243b3f89d490f8d39e3d7f82c61b08fc283627c0279bee4288f93 |
| IEDL.DBID | C6C |
| ISSN | 0031-6970 1432-1041 |
| IngestDate | Thu Aug 21 18:42:42 EDT 2025 Tue Aug 05 09:54:54 EDT 2025 Wed Aug 13 07:58:03 EDT 2025 Wed Feb 19 02:28:15 EST 2025 Tue Jul 01 01:41:20 EDT 2025 Thu Apr 24 23:01:15 EDT 2025 Fri Feb 21 02:48:12 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Therapeutic drug monitoring Personalised medicine Targeted antineoplastic drugs Oral anticancer drugs Tyrosine kinase inhibitors |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c540t-f1f23f893a39243b3f89d490f8d39e3d7f82c61b08fc283627c0279bee4288f93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-9344-8514 |
| OpenAccessLink | https://doi.org/10.1007/s00228-020-03014-8 |
| PMID | 33165648 |
| PQID | 2497365478 |
| PQPubID | 47171 |
| PageCount | 24 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7935845 proquest_miscellaneous_2458964412 proquest_journals_2497365478 pubmed_primary_33165648 crossref_primary_10_1007_s00228_020_03014_8 crossref_citationtrail_10_1007_s00228_020_03014_8 springer_journals_10_1007_s00228_020_03014_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-04-01 |
| PublicationDateYYYYMMDD | 2021-04-01 |
| PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | European journal of clinical pharmacology |
| PublicationTitleAbbrev | Eur J Clin Pharmacol |
| PublicationTitleAlternate | Eur J Clin Pharmacol |
| PublicationYear | 2021 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | IrvinWJWalkoCMWeckKEIbrahimJGChiuWKDeesECMooreSGOlajideOAGrahamMLCanaleSTRaabRECorsoSWPeppercornJMAndersonSMFriedmanKJOgburnETDestaZFlockhartDAMcLeodHLEvansJPCareyLAGenotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter StudyJ Clin Oncol201129323232391:CAS:528:DC%2BC3MXht1ajsrjJ10.1200/jco.2010.31.4427217684733158597 Endo-TsukudeCSasakiJSaekiSIwamotoNInabaMUshijimaSKishiHFujiiSSembaHKashiwabaraKTsubataYHayashiMKaiYSaitoHIsobeTKohrogiHHamadaAPopulation Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and TransportersBiol Pharm Bull20184147561:CAS:528:DC%2BC1cXhslOnsbjK10.1248/bpb.b17-0052129311482 Yu H, van Erp N, Bins S, Mathijssen RHJ, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR (2017) Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients. Clin Pharmacokinet 56:293–303. https://doi.org/10.1007/s40262-016-0443-y GoldwirtLChamiIFeugeasJPPagesCBrunet-PossentiFAllayousCBaroudjianBMadelaineISauvageonHMourahSLebbéCReply to “plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance” by Funck-Brentano et alAnn Oncol2016273633641:STN:280:DC%2BC28vislGiug%3D%3D10.1093/annonc/mdv53826578723 Food and Drug Administration. Center for Drug Evaluation and Research (2019) NDA/BLA Multi‐Disciplinary Review and Evaluation NDA 212526 PIQRAY (alpelisib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212526Orig1s000MultidisciplineR.pdf. Accessed 06 April 2020 Food and Drug Administration. Center for Drug Evaluation and Research (2014) Ceritinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 van NulandMBergmanAMRosingHde VriesNHuitemaADRBeijnenJHExposure-response assessment of enzalutamide and its major metabolites in a real-world cohort of patients with metastatic castration-resistant prostate cancerPharmacotherapy201939113711451:CAS:528:DC%2BB3cXisFanug%3D%3D10.1002/phar.233931596947 BlanchetBBillemontBCramardJBenichouASChhunSHarcouetLRopertSDauphinAGoldwasserFTodMValidation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practiceJ Pharm Biomed Anal200949110911141:CAS:528:DC%2BD1MXjvVyitrk%3D10.1016/j.jpba.2009.02.00819278805 Food and Drug Administration. Center for Drug Evaluation and Research. (2011) Ruxolitinib clinical pharmacology and biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 SternbergCNDonskovFHaasNBDoehnCRussoPElmeliegyMBaneyxGBanerjeeHAimonePMotzerRJPazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinomaClin Cancer Res201824300530131:CAS:528:DC%2BC1cXht1alurnM10.1158/1078-0432.ccr-17-2652293302046748622 Food and Drug Administration. Center for Drug Evaluation and Research (2018) NDA Multi-Disciplinary Review and Evaluation NDA 211349 Xospata (gilteritinib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211349Orig1s000MultidisciplineR.pdf. Accessed 13 February 2020 Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI (2005) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16:1391–1397. https://doi.org/10.1093/annonc/mdi247 Kichenadasse G, Hughes JH, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ (2019) Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-019-04002-1 Liefaard L, Chen C (2015) Quantifying the effectiveness of dose individualization by simulation for a drug with moderate pharmacokinetic variability. Ther Drug Monit 37 ZhouDLiJBuiKLearoydMBergesAMilenkovaTAl-HunitiNTomkinsonHXuHBridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology PatientsClin Pharmacokinet2019586156251:CAS:528:DC%2BC1cXitVSjtLfP10.1007/s40262-018-0714-x30357650 Food and Drug Administration. Center for Drug Evaluation and Research Midostaurin Clinical Pharmacology and Biopharmaceutics Review. Accessed 2020-04-01 ShimadaMOkawaHKondoYMaejimaTKataokaYHisamichiKMaekawaMMatsuuraMJinYMoriMSuzukiHShimosegawaTManoNMonitoring serum levels of sorafenib and its N-oxide is essential for long-term sorafenib treatment of patients with hepatocellular carcinomaTohoku J Exp Med20152371731821:CAS:528:DC%2BC28XhtFelt7fM10.1620/tjem.237.17326477611 Food and Drug Administration. Center for Drug Evaluation and Research (2012) Afatinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s000ClinPharmR.pdf. Accessed 12 February 2020 Food and Drug Administration. Center for Drug Evaluation and Research. (2011) Vandetanib clinical pharmacology and biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 Food and Drug Administration. Center for Drug Evaluation and Research (2011) Crizotinib Clinical Pharmacology and Biopharmaceutics Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf. Accessed 25 Mar 2019 AbbasRHsyuPHClinical Pharmacokinetics and Pharmacodynamics of BosutinibClin Pharmacokinet201655119112041:CAS:528:DC%2BC28XmslSrtb0%3D10.1007/s40262-016-0391-627113346 ZhangMXuCRShamiyehELiuFYinJYVon MoltkeLLSmithWBA randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteersJ Clin Pharmacol2014544154211:CAS:528:DC%2BC2cXhs1ynsbnN10.1002/jcph.21824165976 LacySAMilesDNguyenLClinical pharmacokinetics and pharmacodynamics of cabozantinibClin Pharmacokinet20175647749110.1007/s40262-016-0461-927734291 IngleJNKalariKRBuzdarAURobsonMEGoetzMPDestaZBarmanPDudenkovTTNorthfeltDWPerezEAFlockhartDAWilliardCVWangLWeinshilboumRMEstrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozoleSteroids20159932381:CAS:528:DC%2BC2cXhslGnsLnK10.1016/j.steroids.2014.08.00725163006 Valle M, Salle E Di, Jannuzzo MG, Poggesi I, Rocchetti M, Spinelli R, Verotta D (2005) A predictive model for exemestane pharmacokinetics / pharmacodynamics incorporating the effect of food and formulation. Br J Clin Pharmacol 59:3:355–364. https://doi.org/10.1111/j.1365-2125.2005.02335.x DosneAGValadeEStuyckensKLiLYOuelletDPerez-RuixoJJPopulation Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 StudiesJ Clin Pharmacol2020605155271:CAS:528:DC%2BB3cXksVSgur4%3D10.1002/jcph.154731742712 Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2012) Inlyta European public assessment report. https://www.ema.europa.eu/documents/product-information/inlyta-epar-product-information_en.pdf. Accessed 17 June 2019 NagahamaMOzekiTSuzukiASuginoKNiiokaTItoKMiuraMAssociation of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancerMed Oncol201936391:CAS:528:DC%2BC1MXhtFWqtrfN10.1007/s12032-019-1263-330919115 WelzenMEBDezentjéVOvan SchaikRHNColbersAPHGuchelaarH-Jvan ErpNPden HartighJBurgerDMvan LaarhovenHWMThe Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 ActivityTher Drug Monit2015375015071:CAS:528:DC%2BC2MXht1WrtrrF10.1097/ftd.000000000000019526192892 PartridgeAHAdherence to therapy with oral antineoplastic agentsCancerSpectrum Knowl Environ20029465266110.1093/jnci/94.9.652 RiniBIMelicharBUedaTGrünwaldVFishmanMNArranzJABairAHPithavalaYKAndrewsGIPavlovDKimSJonaschEAxitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trialLancet Oncol201314123312421:CAS:528:DC%2BC3sXhslWlsbjK10.1016/s1470-2045(13)70464-9241401844120767 KramkimelNThomas-SchoemannASakjiLGolmardJLNoeGRegnier-RosencherEChapuisNMaubecEVidalMAvrilMFGoldwasserFMortierLDupinNBlanchetBVemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanomaTarget Oncol20161159691:STN:280:DC%2BC28%2Fmt12nsw%3D%3D10.1007/s11523-015-0375-826208946 Food and Drug Administration. Center for Drug Evaluation and Research (2020) NDA/BLA Multi‐Disciplinary Review and Evaluation NDA 212608 AYVAKIT (avapritinib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212608Orig1s000MultidisciplineR.pdf. Accessed 06 April 2020 Food and Drug Administration. Center for Drug Evaluation and Research (2018) NDA Multi-Disciplinary Review and Evaluation NDA 210498 MEKTOVITM (binimetinib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf. Accessed 13 February 2020 Food and Drug Administration. Center for Drug Evaluation and Research (2015) Osimertinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 CabelLBlanchetBThomas-SchoemannAHuillardOBellesoeurACessotAGirouxJBoudou-RouquettePCoriatRVidalMSaiduNEBGolmardLAlexandreJGoldwasserFDrug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French studyFundam Clin Pharmacol201832981071:CAS:528:DC%2BC2sXhslylsbzM10.1111/fcp.1232729055166 JosephsDHFisherDSSpicerJFlanaganRJClinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoringTher Drug Monit2013355625871:CAS:528:DC%2BC3sXhsFSmsL7E10.1097/ftd.0b013e318292b93124052062 Khosrav B Gao (3014_CR11) 2012; 30 L Aarons (3014_CR31) 2010; 106 NHG Holford (3014_CR33) 2012; 34 M Van Veggel (3014_CR226) 2018; 57 VM Daryani (3014_CR268) 2017; 130 3014_CR175 AH Partridge (3014_CR9) 2002; 94 H Yu (3014_CR12) 2014; 53 SL Groenland (3014_CR55) 2019 N Kramkimel (3014_CR53) 2016; 11 T Suzuki (3014_CR234) 2020; 19 RB Verheijen (3014_CR48) 2016; 22 3014_CR184 S Picard (3014_CR114) 2007; 109 3014_CR181 3014_CR182 3014_CR180 M Deppenweiler (3014_CR21) 2017; 121 3014_CR189 3014_CR187 3014_CR188 E Marostica (3014_CR190) 2015; 75 MF Barginear (3014_CR88) 2011; 90 Y Ishida (3014_CR177) 2016; 72 B Ribba (3014_CR39) 2014; 3 3014_CR195 3014_CR191 3014_CR159 YL Teo (3014_CR120) 2015; 10 3014_CR157 3014_CR278 3014_CR154 E Chatelut (3014_CR23) 2018; 103 3014_CR276 M Tiseo (3014_CR133) 2014; 83 3014_CR273 3014_CR274 E Carton (3014_CR62) 2017; 72 L Klopp-Schulze (3014_CR92) 2020; 11 D Zhou (3014_CR218) 2019; 105 L Nguyen (3014_CR168) 2019; 59 P Fox (3014_CR20) 2016; 22 N Gupta (3014_CR192) 2016; 34 SA Lacy (3014_CR41) 2017; 56 JN Ingle (3014_CR156) 2015; 99 3014_CR161 Y Kurata (3014_CR129) 2015; 1 3014_CR280 3014_CR160 3014_CR169 D Zhou (3014_CR217) 2019; 58 GD Demetri (3014_CR46) 2009; 27 S Hayato (3014_CR196) 2018; 82 3014_CR167 M Protti (3014_CR98) 2019; 1046 Y Hong (3014_CR171) 2017; 57 3014_CR165 YY Zhao (3014_CR4) 2011; 28 R ter Heine (3014_CR109) 2018; 84 MH Diekstra (3014_CR82) 2017; 6 JM Janssen (3014_CR95) 2019; 174 3014_CR14 H Tanii (3014_CR139) 2011; 67 P Saladores (3014_CR84) 2015; 15 MEB Welzen (3014_CR87) 2015; 37 3014_CR173 3014_CR170 DH Josephs (3014_CR38) 2013; 35 M Miura (3014_CR68) 2015; 38 L Madlensky (3014_CR83) 2011; 89 RZ Szmulewitz (3014_CR100) 2018; 36 HA Burris (3014_CR270) 2005; 23 RA Larson (3014_CR45) 2008; 111 M Rousset (3014_CR174) 2017; 472 NAG Lankheet (3014_CR119) 2014; 110 S Mu (3014_CR227) 2016; 72 BI Rini (3014_CR105) 2015; 26 BE Houk (3014_CR60) 2010; 66 EI Heath (3014_CR118) 2010; 88 D Soulieres (3014_CR132) 2004; 22 3014_CR24 SK Sandhu (3014_CR214) 2013; 14 Y Yu (3014_CR250) 2020; 60 S Faivre (3014_CR80) 2006; 24 M Fukudo (3014_CR243) 2014; 53 NGL Jager (3014_CR122) 2014; 143 H Yoshitsugu (3014_CR179) 2012; 43 3014_CR32 Y Wang (3014_CR203) 2008; 48 M van Nuland (3014_CR96) 2019; 1106–1107 NAG Lankheet (3014_CR115) 2014; 36 3014_CR36 I Okamoto (3014_CR211) 2010; 9 K Han (3014_CR258) 2015; 76 C Le Tourneau (3014_CR5) 2009; 101 M Hidalgo (3014_CR131) 2001; 19 NAG Lankheet (3014_CR47) 2014; 110 3014_CR40 MG Sinnollareddy (3014_CR15) 2017 JF Lu (3014_CR134) 2006; 80 Y Fujiwara (3014_CR279) 2009; 100 3014_CR44 3014_CR42 3014_CR43 3014_CR49 D Ouellet (3014_CR172) 2014; 54 N Widmer (3014_CR70) 2006; 62 A Gupta (3014_CR199) 2016; 81 Y Wang (3014_CR10) 2009; 31 L Goldwirt (3014_CR51) 2016; 27 W Sun (3014_CR225) 2017; 57 3014_CR56 AG Dosne (3014_CR183) 2020; 60 SC Tate (3014_CR149) 2018; 57 3014_CR54 3014_CR57 M Herbrink (3014_CR94) 2018; 32 3014_CR58 C Delbaldo (3014_CR117) 2006; 12 S Lacy (3014_CR166) 2018; 81 AA Golabchifar (3014_CR71) 2014; 74 M Nagahama (3014_CR198) 2019; 36 RB Verheijen (3014_CR13) 2017; 102 KT Flaherty (3014_CR224) 2012; 18 3014_CR213 S Noda (3014_CR79) 2015; 13 VO Dezentjé (3014_CR89) 2015; 153 AK Jones (3014_CR277) 2016; 18 N Tsuchiya (3014_CR102) 2015; 33 3014_CR210 RB Verheijen (3014_CR65) 2018; 57 P Boudou-Rouquette (3014_CR245) 2012; 7 E Funck-Brentano (3014_CR52) 2015; 26 3014_CR63 KT Flaherty (3014_CR123) 2012; 367 3014_CR219 3014_CR215 3014_CR216 Z Khalaj (3014_CR91) 2019; 10 L Jain (3014_CR247) 2011; 72 J Donagher (3014_CR28) 2017; 47 3014_CR103 N Takahashi (3014_CR142) 2014; 29 3014_CR104 L Gandhi (3014_CR208) 2014; 32 3014_CR223 3014_CR220 3014_CR221 3014_CR74 P Boudou-Rouquette (3014_CR244) 2012; 17 3014_CR77 3014_CR78 3014_CR229 M Herbrink (3014_CR93) 2016; 38 SL Groenland (3014_CR59) 2019; 30 CN Sternberg (3014_CR75) 2018; 24 DL Hertz (3014_CR281) 2017; 17 B Blanchet (3014_CR246) 2009; 49 S Takasaki (3014_CR121) 2018; 23 D Ouellet (3014_CR50) 2016; 77 S Bouchet (3014_CR69) 2016; 57 R Khosravan (3014_CR81) 2016; 55 D de Wit (3014_CR108) 2016; 78 N Gupta (3014_CR193) 2017; 12 3014_CR85 M Shimada (3014_CR242) 2015; 237 3014_CR86 K Ogasawara (3014_CR186) 2019; 84 FJ Giles (3014_CR140) 2013; 69 CK Lim (3014_CR152) 2018; 103 AT Shaw (3014_CR202) 2017; 18 Z Desta (3014_CR138) 2011; 90 T Tamai (3014_CR197) 2017; 57 M van Nuland (3014_CR264) 2019; 39 3014_CR200 IW Flinn (3014_CR260) 2018; 131 DA Krueger (3014_CR110) 2010; 363 3014_CR201 NP van Erp (3014_CR2) 2009; 35 LA Decosterd (3014_CR22) 2015; 9 3014_CR209 U Schmid (3014_CR212) 2018; 81 M Shipkova (3014_CR111) 2016; 38 3014_CR204 M Savelieva (3014_CR228) 2015; 71 3014_CR205 O Yin (3014_CR206) 2008; 26 H Kobayashi (3014_CR112) 2015; 16 X Wang (3014_CR176) 2013; 5 J Donagher (3014_CR27) 2018; 48 H Minami (3014_CR241) 2008; 99 ME De Jonge (3014_CR29) 2005; 44 3014_CR136 3014_CR257 3014_CR137 H Schmidli (3014_CR72) 2005; 60 3014_CR256 3014_CR7 3014_CR253 3014_CR251 K Brown (3014_CR222) 2017; 83 3014_CR252 WJ Irvin (3014_CR90) 2011; 29 3014_CR1 3014_CR259 A Rousseau (3014_CR26) 2002; 16 V Gotta (3014_CR18) 2014; 74 BI Rini (3014_CR101) 2013; 53 HA Burris (3014_CR282) 2009; 15 AB Suttle (3014_CR61) 2014; 111 RB Verheijen (3014_CR76) 2017; 80 K Nakao (3014_CR151) 2019; 9 D Saltzstein (3014_CR255) 2005; 8 K Stuyckens (3014_CR99) 2014; 53 WS Siegel-Lakhai (3014_CR271) 2007; 13 R Abbas (3014_CR163) 2016; 55 P-H Hsyu (3014_CR162) 2014; 29 3014_CR261 HJ Klümpen (3014_CR3) 2011; 37 S Velghe (3014_CR17) 2018; 410 E Cardoso (3014_CR8) 2018; 57 L Keutzer (3014_CR35) 2020; 11 3014_CR147 3014_CR148 S Sharma (3014_CR267) 2015; 126 3014_CR145 3014_CR266 BI Rini (3014_CR106) 2013; 14 3014_CR146 CA Perez (3014_CR113) 2012; 48 3014_CR265 3014_CR262 3014_CR263 SS De Buck (3014_CR155) 2014; 78 A Ravaud (3014_CR64) 2014; 50 PN Morcos (3014_CR127) 2018; 82 N Gupta (3014_CR194) 2017; 56 E Wang (3014_CR130) 2016; 22 X Chen (3014_CR240) 2013; 53 F Guilhot (3014_CR67) 2012; 97 3014_CR150 3014_CR272 AS Darwich (3014_CR30) 2017; 6 R Nakahara (3014_CR143) 2019; 7 3014_CR235 3014_CR236 C Endo-Tsukude (3014_CR135) 2018; 41 3014_CR233 C Tyrrell (3014_CR254) 1998; 33 3014_CR231 L Alnaim (3014_CR25) 2007; 13 S Mizuta (3014_CR178) 2018; 23 3014_CR232 N Widmer (3014_CR116) 2008; 98 3014_CR239 3014_CR237 3014_CR238 FP Combes (3014_CR66) 2018; 45 OQP Yin (3014_CR207) 2008; 47 JE Cortes (3014_CR230) 2012; 367 A Thiery-Vuillemin (3014_CR107) 2014; 73 C Pérez-Ruixo (3014_CR158) 2019; 59 F Jin (3014_CR269) 2016; 77 S Farag (3014_CR73) 2017; 56 L Cabel (3014_CR19) 2018; 32 EMJ van Brummelen (3014_CR6) 2016; 43 PH Hsyu (3014_CR164) 2013; 71 3014_CR125 3014_CR126 M Herbrink (3014_CR37) 2017; 34 G Reda (3014_CR275) 2019; 104 3014_CR124 M Freiwald (3014_CR153) 2014; 73 CM Nijenhuis (3014_CR144) 2017; 57 JA Abrantes (3014_CR34) 2019; 85 3014_CR248 3014_CR128 3014_CR249 MGM Kok (3014_CR97) 2018; 147 M Zhang (3014_CR185) 2014; 54 SG Wicha (3014_CR16) 2015; 45 RA Larson (3014_CR141) 2012; 68 33320282 - Eur J Clin Pharmacol. 2020 Dec 15 |
| References_xml | – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2013) Dabrafenib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2014) CHMP Regorafenib Extension of Indication Variation Assessment Report. https://www.ema.europa.eu/en/documents/variation-report/stivarga-h-c-2573-ii-0001-epar-assessment-report-variation_en.pdf. Accessed 12 February 2020 – reference: FaragSVerheijenRBMartijn KerstJCatsAHuitemaADRSteeghsNImatinib pharmacokinetics in a large observational cohort of gastrointestinal stromal tumour patientsClin Pharmacokinet2017562872921:CAS:528:DC%2BC28Xht1ehur7J10.1007/s40262-016-0439-727435281 – reference: WangENickensDJBelloAKhosravanRAmanteaMWilnerKDParivarKTanWClinical implications of the pharmacokinetics of crizotinib in populations of patients with non-small cell lung cancerClin Cancer Res201622572257281:CAS:528:DC%2BC28XitVegt7rJ10.1158/1078-0432.ccr-16-053627281559 – reference: Food and Drug Administration. Center for Drug Evaluation and Research Midostaurin Clinical Pharmacology and Biopharmaceutics Review. Accessed 2020-04-01 – reference: MiuraMTherapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemiaBiol Pharm Bull2015386456541:CAS:528:DC%2BC2MXhtlGrtLnL10.1248/bpb.b15-00103 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2019) NDA/BLA Multi-disciplinary Review and Evaluation NDA 211810 TURALIO (pexidartinib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211810Orig1s000MultidisciplineR.pdf. Accessed 06 April 2020 – reference: Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, van der Graaf WTA, van Erp NP (2017) Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol 83:2195–2204. https://doi.org/10.1111/bcp.13327 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2014) Ceritinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 – reference: CardosoECsajkaCSchneiderMPWidmerNEffect of adherence on pharmacokinetic/pharmacodynamic relationships of oral targeted anticancer drugsClin Pharmacokinet201857161:CAS:528:DC%2BC2sXhtVOntb%2FP10.1007/s40262-017-0571-z28634655 – reference: Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP (2019) The effect of using pazopanib with food vs. fasted on pharmacokinetics, patient safety, and preference (DIET study). Clin Pharmacol Ther 106:1076–1082. https://doi.org/10.1002/cpt.1515 – reference: Valle M, Salle E Di, Jannuzzo MG, Poggesi I, Rocchetti M, Spinelli R, Verotta D (2005) A predictive model for exemestane pharmacokinetics / pharmacodynamics incorporating the effect of food and formulation. Br J Clin Pharmacol 59:3:355–364. https://doi.org/10.1111/j.1365-2125.2005.02335.x – reference: RoussetMDutriauxCBosco-LévyPPreySPham-LedardADoussetLGérardEBouchetSCanal-RaffinMTitierKMolimardMTrough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanomaClin Chim Acta201747226291:CAS:528:DC%2BC2sXhtFyitbjK10.1016/j.cca.2017.07.01228709799 – reference: Janssen JM, Dorlo TPC, Beijnen JH, Huitema ADR Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs. Ther Drug Monit. https://doi.org/10.1097/ftd.0000000000000767 – reference: FlahertyKTLoRussoPMDeMicheleAAbramsonVGCourtneyRRandolphSSShaikMNWilnerKDO’DwyerPJSchwartzGKPhase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerClin Cancer Res2012185685761:CAS:528:DC%2BC38XhtVGqs7o%3D10.1158/1078-0432.ccr-11-050922090362 – reference: TsuchiyaNIgarashiRSuzuki-HonmaNFujiyamaNNaritaSInoueTSaitoMAkihamaSTsurutaHMiuraMHabuchiTAssociation of pharmacokinetics of axitinib with treatment outcome and adverse events in advanced renal cell carcinoma patientsJ Clin Oncol20153350610.1200/jco.2015.33.7_suppl.506 – reference: TeoYLChueXPChauNMTanMHKanesvaranRWeeHLHoHKChanAAssociation of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinibTarget Oncol20151042943710.1007/s11523-014-0349-225502986 – reference: JanssenJMde VriesNVenekampNRosingHHuitemaADRBeijnenJHDevelopment and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasmaJ Pharm Biomed Anal20191745615661:CAS:528:DC%2BC1MXht1OjsL%2FN10.1016/j.jpba.2019.06.03431255856 – reference: De BuckSSJakabABoehmMBootleDJuricDQuadtCGogginTKPopulation pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignanciesBr J Clin Pharmacol2014785435551:CAS:528:DC%2BC2cXhsVWltbbF10.1111/bcp.12378246176314243905 – reference: VerheijenRBSwartLEBeijnenJHSchellensJHMHuitemaADRSteeghsNExposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimizationCancer Chemother Pharmacol201780117111781:CAS:528:DC%2BC2sXhs12ltrvI10.1007/s00280-017-3463-x290519955686255 – reference: IngleJNKalariKRBuzdarAURobsonMEGoetzMPDestaZBarmanPDudenkovTTNorthfeltDWPerezEAFlockhartDAWilliardCVWangLWeinshilboumRMEstrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozoleSteroids20159932381:CAS:528:DC%2BC2cXhslGnsLnK10.1016/j.steroids.2014.08.00725163006 – reference: IrvinWJWalkoCMWeckKEIbrahimJGChiuWKDeesECMooreSGOlajideOAGrahamMLCanaleSTRaabRECorsoSWPeppercornJMAndersonSMFriedmanKJOgburnETDestaZFlockhartDAMcLeodHLEvansJPCareyLAGenotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter StudyJ Clin Oncol201129323232391:CAS:528:DC%2BC3MXht1ajsrjJ10.1200/jco.2010.31.4427217684733158597 – reference: LankheetNAGKnapenLMSchellensJHMBeijnenJHSteeghsNHuitemaADRPlasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer careTher Drug Monit2014363263341:CAS:528:DC%2BC2cXotFCrtr4%3D10.1097/ftd.000000000000000424305627 – reference: DosneAGValadeEStuyckensKLiLYOuelletDPerez-RuixoJJPopulation Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 StudiesJ Clin Pharmacol2020605155271:CAS:528:DC%2BB3cXksVSgur4%3D10.1002/jcph.154731742712 – reference: Lin S, Shaik N, Martinelli G, Wagner AJ, Cortes J, Ruiz-Garcia A (2019) Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. J Clin Pharmacol. https://doi.org/10.1002/jcph.1556 – reference: WidmerNDecosterdLACsajkaCLeyvrazSDuchosalMARosseletARochatBEapCBHenryHBiollazJBuclinTPopulation pharmacokinetics of imatinib and the role of α1-acid glycoproteinBr J Clin Pharmacol200662971121:CAS:528:DC%2BD28XoslKnsL4%3D10.1111/j.1365-2125.2006.02719.x168423821885072 – reference: RiniBIGarrettMPolandBDutcherJPRixeOWildingGStadlerWMPithavalaYKKimSTaraziJMotzerRJAxitinib in metastatic renal cell carcinoma: Results of a pharmacokinetic and pharmacodynamic analysisJ Clin Pharmacol2013534915041:CAS:528:DC%2BC2cXhs1yntrbP10.1002/jcph.73235535604175417 – reference: SandhuSKSchelmanWRWildingGMorenoVBairdRDMirandaSHylandsLRiisnaesRForsterMOmlinAKreischerNThwayKGevenslebenHSunLLoughneyJChatterjeeMToniattiCCarpenterCLIannoneRKayeSBde BonoJSWenhamRMThe poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trialLancet Oncol2013148828921:CAS:528:DC%2BC3sXhtVOjtLnF10.1016/s1470-2045(13)70240-723810788 – reference: MadlenskyLNatarajanLTchuSPuMMortimerJFlattSWNikoloffDMHillmanGFontechaMRLawrenceHJParkerBAWuAHBPierceJPTamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomesClin Pharmacol Ther2011897187251:CAS:528:DC%2BC3MXltVGnt74%3D10.1038/clpt.2011.3221430657 – reference: GroenlandSLVan EerdenRAGKoolenSLMoesDJARDesarIMETouwDJImholzALTReynersAKLGelderblomHvan ErpNPMathijssenRHJHuitemaADRSteeghsNTherapeutic drug monitoring of oral anticancer drugs—preliminary results of a prospective studyAnn Oncol201930442O10.1093/annonc/mdz244.004 – reference: GaoBYeapSClementsABalakrishnarBWongMGurneyHEvidence for therapeutic drug monitoring of targeted anticancer therapiesJ Clin Oncol201230401740251:CAS:528:DC%2BC38XhvValtbfJ10.1200/jco.2012.43.536222927532 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2014) Nintedanib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2018) Abemaciclib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208855Orig1s000MultidisciplineR.pdf. Accessed 12 February 2020 – reference: DezentjéVOOpdamFLGelderblomHHartighd JVan der StraatenTVreeRMaartenseESmorenburgCHPutterHDieudonnéASNevenPVan de VeldeCJHNortierJWRGuchelaarHJCYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effectsBreast Cancer Res Treat20151535835901:CAS:528:DC%2BC2MXhsFartb7J10.1007/s10549-015-3562-5263695334589558 – reference: KlümpenHJSamerCFMathijssenRHJSchellensJHMGurneyHMoving towards dose individualization of tyrosine kinase inhibitorsCancer Treat Rev2011372512601:CAS:528:DC%2BC3MXktFGls7w%3D10.1016/j.ctrv.2010.08.00620833478 – reference: KruegerDACareMMHollandKAgricolaKTudorCMangeshkarPWilsonKAByarsASahmoudTFranzDNEverolimus for subependymal giant-cell astrocytomas in tuberous sclerosisN Engl J Med2010363180118111:CAS:528:DC%2BC3cXhtl2gsbbP10.1056/nejmoa100167121047224 – reference: BurrisHAHurwitzHIDeesECDowlatiABlackwellKLO’NeilBMarcomPKEllisMJOvermoyerBJonesSFHarrisJLSmithDAKochKMSteadAMangumSSpectorNLPhase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasJ Clin Oncol200523530553131:CAS:528:DC%2BD2MXpslOrtL0%3D10.1200/jco.2005.16.58415955900 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2020) NDA/BLA Multi‐Disciplinary Review and Evaluation NDA 212608 AYVAKIT (avapritinib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212608Orig1s000MultidisciplineR.pdf. Accessed 06 April 2020 – reference: SaladoresPMürdterTEcclesDChowbayBZgheibNKWinterSGanchevBEcclesBGertySTfayliALimJSLYapYSNgRCHWongNSDentRHabbalMZSchaeffelerEEichelbaumMSchrothWSchwabMBrauchHTamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancerPharm J20151584941:CAS:528:DC%2BC2cXht1KksbrF10.1038/tpj.2014.34 – reference: Zhang J, Koch K (2012) Population pharmacokinetics of Lapatinib in cancer patients. PAGE Meet. https://doi.org/10.1007/s40262-016-0452-x – reference: Yu H, van Erp N, Bins S, Mathijssen RHJ, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR (2017) Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients. Clin Pharmacokinet 56:293–303. https://doi.org/10.1007/s40262-016-0443-y – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2018) NDA Multi-Disciplinary Review and Evaluation NDA 211349 Xospata (gilteritinib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211349Orig1s000MultidisciplineR.pdf. Accessed 13 February 2020 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2015) Osimertinib European Public Assessment Report. https://www.ema.europa.eu/en/documents/assessment-report/tagrisso-epar-public-assessment-report_en.pdf. Accessed 13 February 2020 – reference: VerheijenRBAtrafiFSchellensJHMBeijnenJHHuitemaADRMathijssenRHJSteeghsNPharmacokinetic optimization of everolimus dosing in oncology: a randomized crossover trialClin Pharmacokinet2018576376441:CAS:528:DC%2BC2sXht1Kqur7E10.1007/s40262-017-0582-928762135 – reference: DestaZKreutzYNguyenATLiLSkaarTKamdemLKHenryNLHayesDFStornioloAMStearnsVHoffmannETyndaleRFFlockhartDAPlasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and ageClin Pharmacol Ther2011906937001:CAS:528:DC%2BC3MXhtlGlsLjF10.1038/clpt.2011.17421975350 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2019) NDA/BLA multi-disciplinary review and evaluation NDA 212725 ROZLYTREK (entrectinib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212725Orig1s000, 212726Orig1s000MultidisciplineR.pdf. Accessed 14 February 2020 – reference: Noda S, Yoshida T, Hira D, Murai R, Tomita K, Tsuru T, Kageyama S, Kawauchi A, Ikeda Y, Morita S y, Terada T (2018) Exploratory investigation of target pazopanib concentration range for patients with renal cell carcinoma. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2018.12.001 – reference: NguyenLChapelSTranBDLacySUpdated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular CarcinomaJ Clin Pharmacol201959155115611:CAS:528:DC%2BC1MXhvVOmurzJ10.1002/jcph.1467311875156790584 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2017) Niraparib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208447Orig1s000MultidisciplineR.pdf. Accessed 31 March 2020 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2012) Regorafenib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000ClinPharmR.pdf. Accessed 12 February 2020 – reference: van NulandMVenekampNde VriesNde JongKAMRosingHBeijnenJHDevelopment and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncologyJ Chromatogr B20191106–110726341:CAS:528:DC%2BC1MXntFCgsg%3D%3D10.1016/j.jchromb.2019.01.001 – reference: NagahamaMOzekiTSuzukiASuginoKNiiokaTItoKMiuraMAssociation of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancerMed Oncol201936391:CAS:528:DC%2BC1MXhtFWqtrfN10.1007/s12032-019-1263-330919115 – reference: TateSCSykesAKKulanthaivelPChanEMTurnerPKCronierDMA Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer PatientsClin Pharmacokinet2018573353441:CAS:528:DC%2BC2sXosl2rsbw%3D10.1007/s40262-017-0559-828540640 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2017) Vemurafenib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/202429Orig1s016ClinPharmR.pdf. Accessed 24 March 2020 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2017) NDA Multi-Disciplinary Review and Evaluation NDA 208772 ALUNBRIG (brigatinib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf. Accessed 12 February 2020 – reference: de WitDSchneiderTCMoesDJARRoozenCFMden HartighJGelderblomHGuchelaarHJvan der HoevenJJLinksTPKapiteijnEvan ErpNPEverolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancerCancer Chemother Pharmacol20167863711:CAS:528:DC%2BC28XnvFWksbo%3D10.1007/s00280-016-3050-6271697924921118 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2012) Axitinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000ClinPharmR.pdf. Accessed 18 June 2019 – reference: Nguyen L, Chapel S, Duy B, Lacy S (2019) Cabozantinib exposure – response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma. J Pharmacokinet Pharmacodyn 0123456789. https://doi.org/10.1007/s10928-019-09659-y – reference: ChatelutEBrunoRRatainMJIntraindividual pharmacokinetic variability: focus on small-molecule kinase inhibitorsClin Pharmacol Ther201810395695810.1002/cpt.93729194586 – reference: Drennan P, Doogue M, van Hal SJ, Chin P (2018) Bayesian therapeutic drug monitoring software: past, present and future. Int J Pharm 3:109–114. https://doi.org/10.4155/ipk-2018-0005 – reference: YoshitsuguHImaiYSeriuTHiraokaMMarkov Chain Monte Carlo Bayesian analysis for population pharmacokinetics of dasatinib in Japanese adult subjects with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemiaJapanese J Clin Pharmacol Ther20124329411:CAS:528:DC%2BC38XjvFOksr0%3D10.3999/jscpt.43.29 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2018) NDA Multi-Disciplinary Review and Evaluation NDA 210496 BRAFTOVITM (encorafenib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210496Orig1s000MultidisciplineR.pdf. Accessed 12 February 2020 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2019) Vitrakvi European public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/vitrakvi-epar-public-assessment-report_en.pdf. – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2012) Afatinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s000ClinPharmR.pdf. Accessed 12 February 2020 – reference: BlanchetBBillemontBCramardJBenichouASChhunSHarcouetLRopertSDauphinAGoldwasserFTodMValidation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practiceJ Pharm Biomed Anal200949110911141:CAS:528:DC%2BD1MXjvVyitrk%3D10.1016/j.jpba.2009.02.00819278805 – reference: Food and Drug Administration. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. (2010) Guidance for industry—pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labelling. Draft Guidance Document. https://www.fda.gov/media/78573/download. Accessed 23 March 2020 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2019) NDA/BLA Multi‐Disciplinary Review and Evaluation NDA 212526 PIQRAY (alpelisib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212526Orig1s000MultidisciplineR.pdf. Accessed 06 April 2020 – reference: SchmidliHCapdevilleRHensleyMPengBGathmannIRacine-PoonARiviereG-JBoltonAEPopulation pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III studyBr J Clin Pharmacol20056035441:CAS:528:DC%2BD2MXmvF2ktrw%3D10.1111/j.1365-2125.2005.02372.x159630921884912 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2013) Trametinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204114Orig1s000ClinPharmR.pdf. Accessed 24 March 2020 – reference: DarwichASOgungbenroKHatleyOJRostami-HodjeganARole of pharmacokinetic modeling and simulation in precision dosing of anticancer drugsTransl Cancer Res20176S1512S15291:CAS:528:DC%2BC1cXitFOrsL7L10.21037/tcr.2017.09.14 – reference: HsyuPHMouldDRUptonRNAmanteaMPharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemiaCancer Chemother Pharmacol2013712092181:CAS:528:DC%2BC3sXktFCjsQ%3D%3D10.1007/s00280-012-1998-423070145 – reference: HerbrinkMde VriesNRosingHHuitemaADRNuijenBSchellensJHMBeijnenJHQuantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass SpectrometryTher Drug Monit2016386496561:CAS:528:DC%2BC28XhvVyhu7jF10.1097/ftd.000000000000034927749781 – reference: YuHSteeghsNNijenhuisCMSchellensJHMBeijnenJHHuitemaADRPractical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targetsClin Pharmacokinet2014533053251:CAS:528:DC%2BC2cXltFensb8%3D10.1007/s40262-014-0137-224566736 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2013) Regorafenib European Public Assessment Report. https://www.ema.europa.eu/en/documents/assessment-report/stivarga-epar-public-assessment-report_en.pdf. – reference: LarsonRADrukerBJGuilhotFO’BrienSGRiviereGJKrahnkeTGathmannIWangYImatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyBlood2008111402240281:CAS:528:DC%2BD1cXkvFeisrg%3D10.1182/blood-2007-10-11647518256322 – reference: PartridgeAHAdherence to therapy with oral antineoplastic agentsCancerSpectrum Knowl Environ20029465266110.1093/jnci/94.9.652 – reference: TakasakiSKawasakiYKikuchiMTanakaMSuzukaMNodaASatoYYamashitaSMitsuzukaKSaitoHItoAYamaguchiHAraiYManoNRelationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinomaInt J Clin Oncol2018239369431:CAS:528:DC%2BC1cXhtVOls7bO10.1007/s10147-018-1302-729860539 – reference: Thiery-VuilleminAMouilletGNguyen Tan HonTMontcuquetPMaurinaTAlmotlakHSteinUMontangeDFoubertANerichVPivotXRoyerBImpact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinomaCancer Chemother Pharmacol20147399910071:CAS:528:DC%2BC2cXltFyhsb4%3D10.1007/s00280-014-2435-724682543 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2014) Nintedanib European Public Assessment Report. https://www.ema.europa.eu/en/documents/assessment-report/vargatef-epar-public-assessment-report_en.pdf. Accessed 13 February 2020 – reference: DemetriGDWangYWehrleERacineANikolovaZBlankeCDJoensuuHVon MehrenMImatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumorsJ Clin Oncol200927314131471:CAS:528:DC%2BD1MXhtFWitb3K10.1200/jco.2008.20.481819451435 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2018) NDA multi-disciplinary review and evaluation NDA 210861 and NDA 211710 VITRAKVI (larotrectinib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210861Orig1s000_211710Orig1s000MultidisciplineR.pdf. Accessed 14 February 2020 – reference: CombesFPGuillaumeCNevaBPennyCWilliamZYinHNedelmanJPopulation pharmacokinetics—pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complexJ Pharmacokinet Pharmacodyn2018457077191:CAS:528:DC%2BC1cXhtlWntr3L10.1007/s10928-018-9600-229992479 – reference: BouchetSPouletteSTitierKMooreNLassalleRAbouelfathAItalianoAChevreauCBompasECollardODuffaudFRiosMCupissolDAdenisARay-CoquardIBouchéOLe CesneABuiBBlayJYMolimardMRelationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life settingEur J Cancer20165731381:CAS:528:DC%2BC28XhsFKms7Y%3D10.1016/j.ejca.2015.12.02926851399 – reference: StuyckensKSaadFXuXSRyanCJSmithMRGriffinTWYuMKVermeulenANandyPPoggesiIPopulation Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Naïve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate CancerClin Pharmacokinet201453114911601:CAS:528:DC%2BC2cXhsFKrtrvL10.1007/s40262-014-0178-625204404 – reference: DonagherJMartinJHBarrasMAIndividualised medicine: why we need Bayesian dosingIntern Med J20174759360010.1111/imj.1341228503880 – reference: RiniBIMelicharBFishmanMNOyaMPithavalaYKChenYBairAHGrünwaldVAxitinib dose titration: Analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinomaAnn Oncol201526137213771:STN:280:DC%2BC2MrnsVGhtg%3D%3D10.1093/annonc/mdv10325701454 – reference: Food and Drug Administration. Center for Drug Evaluation and Research. (2011) Ruxolitinib clinical pharmacology and biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2017) Tivozanib European public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/fotivda-epar-public-assessment-report_en.pdf. – reference: RavaudAUrvaSRGroschKCheungWKAnakOSellamiDBRelationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncologyEur J Cancer2014504864951:CAS:528:DC%2BC3sXitVShurvL10.1016/j.ejca.2013.11.02224332451 – reference: GilesFJYinOQPSallasWMLe CoutrePDWoodmanRCOttmannOGBaccaraniMKantarjianHMNilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemiaEur J Clin Pharmacol20136981382310.1007/s00228-012-1385-423052406 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2018) NDA Multi-Disciplinary Review and Evaluation NDA 211192 Tibsovo (ivosidenib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211192Orig1s000MultidisciplineR.pdf. Accessed 06 April 2020 – reference: RedaGCassinRDovrtelovaGMatteoCGiannottaJD’incalciMCortelezziAZucchettiMVenetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvementHaematologica2019104e222e2231:CAS:528:DC%2BC1MXitVGjt7jL10.3324/haematol.2018.213157307654726518888 – reference: KeutzerLSimonssonUSHIndividualized dosing with high inter-occasion variability is correctly handled with model-informed precision dosing—using rifampicin as an exampleFront Pharmacol2020111151:CAS:528:DC%2BB3cXhvFKksbvL10.3389/fphar.2020.00794 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2014) Olaparib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206162Orig1s000ClinPharmR.pdf. Accessed 14 February 2020 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2017) NDA/BLA multi-disciplinary review and evaluation NDA 209092 KISQALI (ribociclib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209092Orig1s000MultidisciplineR.pdf. Accessed 13 February 2020 – reference: TyrrellCDenisLNewlingDSolowayMChannerKCockshottICasodex TM 10–200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancerEur Urol19983339531:CAS:528:DyaK1cXlsVajsbs%3D10.1159/000019526 – reference: TaniiHShitaraYHorieTPopulation pharmacokinetic analysis of letrozole in Japanese postmenopausal womenEur J Clin Pharmacol201167101710.1007/s00228-011-1042-321494765 – reference: ter HeineRvan ErpNPGuchelaarHJde FijterJWReindersMEJvan HerpenCMBurgerDMMoesDJARA pharmacological rationale for improved everolimus dosing in oncology and transplant patientsBr J Clin Pharmacol201884157515861:CAS:528:DC%2BC1cXhtFOntbbE10.1111/bcp.13591295749746005589 – reference: AlnaimLTherapeutic drug monitoring of cancer chemotherapyJ Oncol Pharm Pract2007132072211:CAS:528:DC%2BD1cXitVOgtLw%3D10.2165/00003088-199018040-0000418045780 – reference: GolabchifarAARezaeeSGhavamzadehAAlimoghaddamKDinanNMRouiniMRPopulation pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemiaCancer Chemother Pharmacol20147485931:CAS:528:DC%2BC2cXnvFelurs%3D10.1007/s00280-014-2473-124817601 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2018) Glasdegib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210656Orig1s000ClinPharmR.pdf. Accessed 06 April 2020 – reference: ChenXWilliamsWVSandorVYeleswaramSPopulation pharmacokinetic analysis of orally-administered ruxolitinib (incb018424 phosphate) in patients with primary myelofibrosis (pmf), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF)J Clin Pharmacol20135372173010.1002/jcph.10223677817 – reference: BurrisHATaylorCWJonesSFKochKMVersolaMJAryaNFlemingRASmithDAPanditeLSpectorNWildingGA phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignanciesClin Cancer Res200915670267081:CAS:528:DC%2BD1MXhtlCjsrfJ10.1158/1078-0432.ccr-09-0369198259483232441 – reference: FukudoMItoTMizunoTShinsakoKHatanoEUemotoSKambaTYamasakiTOgawaOSenoHChibaTMatsubaraKExposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinomaClin Pharmacokinet2014531851961:CAS:528:DC%2BC2cXhsFChsr0%3D10.1007/s40262-013-0108-z24135988 – reference: GuptaNDiderichsenPMHanleyMJBergDvan de VeldeHHarveyRDVenkatakrishnanKPopulation Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform LabellingClin Pharmacokinet201756135513681:CAS:528:DC%2BC2sXksVOlur4%3D10.1007/s40262-017-0526-4282901215648746 – reference: KobayashiHSatoKNiiokaTMiuraHItoHMiuraMRelationship among gefitinib exposure, polymorphisms of its metabolizing enzymes and transporters, and side effects in Japanese patients with non-small-cell lung cancerClin Lung Cancer2015162742811:CAS:528:DC%2BC2MXhtVShs7fP10.1016/j.cllc.2014.12.00425554506 – reference: LankheetNAGKlothJSLGadellaa-Van HooijdonkCGMCirkelGAMathijssenRHJLolkemaMPJKSchellensJHMVoestEESleijferSDe JongeMJAHaanenJBAGBeijnenJHHuitemaADRSteeghsNPharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumoursBr J Cancer2014110244124491:CAS:528:DC%2BC2cXmsFagu7Y%3D10.1038/bjc.2014.194247365814021528 – reference: JagerNGLRosingHSchellensJHMLinnSCBeijnenJHTamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient careBreast Cancer Res Treat20141434774831:CAS:528:DC%2BC2cXjtlCgsg%3D%3D10.1007/s10549-013-2826-124390246 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2019) Lorviqua European public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/lorviqua-epar-public-assessment-report_en.pdf. Accessed 14 February 2020 – reference: KokMGMFilletMVolumetric absorptive microsampling: Current advances and applicationsJ Pharm Biomed Anal20181472882961:CAS:528:DC%2BC2sXhtlWksLbP10.1016/j.jpba.2017.07.02928803682 – reference: YuYDurairajCShiHWangDDPopulation pharmacokinetics of talazoparib in patients with advanced cancerJ Clin Pharmacol2020602182281:CAS:528:DC%2BB3cXjslakuw%3D%3D10.1002/jcph.152031489639 – reference: Food and Drug Administration. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. (2003) Guidance for industry—pharmacokinetics in patients with impaired hepatic function—study design, data analysis, and impact on dosing and labelling. Draft Guidance Document. https://www.fda.gov/media/71311/download. Accessed 23 March 2020 – reference: WidmerNDecosterdLALeyvrazSDuchosalMARosseletADebiec-RychterMCsajkaCBiollazJBuclinTRelationship of imatinib-free plasma levels and target genotype with efficacy and tolerabilityBr J Cancer200898163316401:CAS:528:DC%2BD1cXlvVWhsbs%3D10.1038/sj.bjc.6604355184752962391118 – reference: HongYPassosVQHuangPHLauYYPopulation Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma KinaseJ Clin Pharmacol2017576526621:CAS:528:DC%2BC2sXlvFeqsL4%3D10.1002/jcph.84927922734 – reference: JinFGaoYZhouHFangLLiXPopulation pharmacokinetic modeling of idelalisib , a novel PI3K δ inhibitor , in healthy subjects and patients with hematologic malignanciesCancer Chemother Pharmacol20167789981:CAS:528:DC%2BC2MXitVagtrbP10.1007/s00280-015-2891-826645408 – reference: PicardSTitierKEtienneGTeilhetEDucintDBernardMALassalleRMaritGReiffersJBegaudBMooreNMolimardMMahonFXTrough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaBlood2007109349634991:CAS:528:DC%2BD2sXksFWhsrY%3D10.1182/blood-2006-07-03601217192396 – reference: Funck-BrentanoEAlvarezJCLongvertCAbeEBeauchetAFunck-BrentanoCSaiagPPlasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and toleranceAnn Oncol201526147014751:STN:280:DC%2BC2Mjms1Okug%3D%3D10.1093/annonc/mdv18925899783 – reference: VerheijenRBYuHSchellensJHMBeijnenJHSteeghsNHuitemaADRPractical recommendations for therapeutic drug monitoring of kinase inhibitors in oncologyClin Pharmacol Ther201710276577610.1002/cpt.787286991605656880 – reference: ShipkovaMHesselinkDAHoltDWBillaudEMVan GelderTKunickiPKBrunetMBuddeKBartenMJDe SimonePWielandELopezOMMasudaSSegerCPicardNOellerichMLangmanLJWallemacqPMorrisRGThompsonCMarquetPTherapeutic drug monitoring of everolimus: A consensus reportTher Drug Monit2016381431691:CAS:528:DC%2BC28XksVGqu74%3D10.1097/ftd.000000000000026026982492 – reference: Groenland SL, van Nuland M, Verheijen RB, Schellens JHM, Beijnen JH, Huitema ADR, Steeghs N (2018) Therapeutic drug monitoring of oral anti-hormonal drugs in oncology. Clin Pharmacokinet https://doi.org/10.1007/s40262-018-0683-0 – reference: Siegel-LakhaiWSBeijnenJHVervenneWLBootHKeessenMVersolaMKochKMSmithDAPanditeLRichelDJSchellensJHMPhase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumorsClin Cancer Res200713449545021:CAS:528:DC%2BD2sXotlGqtbs%3D10.1158/1078-0432.ccr-07-000417671135 – reference: DelbaldoCChatelutERéMDeroussentASéronie-VivienSJambuABerthaudPLe CesneABlayJYVassalGPharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumorsClin Cancer Res200612607360781:CAS:528:DC%2BD28XhtFWhsbnO10.1158/1078-0432.ccr-05-259617062683 – reference: HayatoSSchumakerRFerryJBinderTDuctusCEHusseinZExposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancerCancer Chemother Pharmacol20188297197810.1007/s00280-018-3687-4302443186267706 – reference: van NulandMBergmanAMRosingHde VriesNHuitemaADRBeijnenJHExposure-response assessment of enzalutamide and its major metabolites in a real-world cohort of patients with metastatic castration-resistant prostate cancerPharmacotherapy201939113711451:CAS:528:DC%2BB3cXisFanug%3D%3D10.1002/phar.233931596947 – reference: PerezCASongHRaezLEAgulnikMGrushkoTADekkerAStensonKBlairEAOlopadeOISeiwertTYVokesEECohenEEWPhase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neckOral Oncol2012488878921:CAS:528:DC%2BC38XlvVSltrg%3D10.1016/j.oraloncology.2012.03.02022513208 – reference: Boudou-RouquettePNarjozCGolmardJLThomas-SchoemannAMirOTaiebFDurandJPCoriatRDauphinAVidalMTodMLoriotMAGoldwasserFBlanchetBEarly sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary studyPLoS One20127191:CAS:528:DC%2BC38Xht1amsrzN10.1371/journal.pone.0042875 – reference: Food and Drug Administration. Center for Drug Evaluation and Research. (2012) Vismodegib clinical pharmacology and biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203388Orig1s000ClinPharmR.pdf. Accessed 12 Februrary 2020 – reference: HolfordNHGBuclinTSafe and effective variability—a criterion for dose individualizationTher Drug Monit2012345655681:CAS:528:DC%2BC38XhtlGmsrbP10.1097/ftd.0b013e31826aabc322960736 – reference: DonagherJBarrasMATherapeutic drug monitoring: using Bayesian methods to evaluate hospital practiceJ Pharm Pract Res20184852252910.1002/jppr.1432 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2018) Dacomitinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf. Accessed 13 February 2020 – reference: Eechoute K, Fransson MN, Reyners AK, De Jong FA, Sparreboom A, Van Der Graaf WTA, Friberg LE, Schiavon G, Wiemer EAC, Verweij J, Loos WJ, Mathijssen RHJ, De Giorgi U (2012) A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 18:5780–5787. https://doi.org/10.1158/1078-0432.ccr-12-0490 – reference: CartonENoeGHuillardOGolmardLGirouxJCessotASaiduNEBPeyromaureMZerbibMNarjozCGuibourdencheJThomasAVidalMGoldwasserFBlanchetBAlexandreJRelation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patientsEur J Cancer20177254611:CAS:528:DC%2BC28XitFSlsbrF10.1016/j.ejca.2016.11.02728027516 – reference: AaronsLOgungbenroKOptimal design of pharmacokinetic studiesBasic Clin Pharmacol Toxicol20101062502551:CAS:528:DC%2BC3cXivVShur4%3D10.1111/j.1742-7843.2009.00533.x20102362 – reference: DecosterdLAWidmerNZamanKCardosoEBuclinTCsajkaCTherapeutic drug monitoring of targeted anticancer therapyBiomark Med201598878931:CAS:528:DC%2BC2MXhsFKktrzO10.2217/bmm.15.7826333311 – reference: Food and Drug Administration. Center for Drug Evaluation and Research. (2016) Venetoclax clinical pharmacology and biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208573Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 – reference: FujiwaraYYamamotoNYamadaYYamadaKOtsukiTKanazuSIwasaTHardwickJSTamuraTPhase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumorsCancer Sci2009100172817341:CAS:528:DC%2BD1MXhtFOhurnI10.1111/j.1349-7006.2009.01237.x19575752 – reference: Wollenberg L, Marchand M, Merdjan H, Litwiler K (2018) Development of a Population Pharmacokinetic Model for Binimetinib with Subsequent Exposure-Response Analyses in NRAS Mutant Melanoma. Am Conf Pharmacometrics – reference: Committee for Medicinal Products for Human Use European Medicines Agency (2017) Alecensa European public assessment report. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Accessed 07 April 2019 – reference: YinOQPWangYSchranHA mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjectsClin Pharmacokinet2008478078161:CAS:528:DC%2BD1MXislSqt7Y%3D10.2165/0003088-200847120-0000519026036 – reference: Le TourneauCLeeJJSiuLLDose escalation methods in phase I cancer clinical trialsJ Natl Cancer Inst20091017087201:CAS:528:DC%2BD1MXmtlyit7w%3D10.1093/jnci/djp079194360292684552 – reference: TamaiTHayatoSHojoSSuzukiTOkusakaTIkedaKKumadaHDose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response AnalysesJ Clin Pharmacol201757113811471:CAS:528:DC%2BC2sXhtlemt7rM10.1002/jcph.917285619185575539 – reference: CortesJEKantarjianHShahNPBixbyDMauroMJFlinnIO’HareTHuSNarasimhanNIRiveraVMClacksonTTurnerCDHaluskaFGDrukerBJDeiningerMWNTalpazMPonatinib in refractory Philadelphia chromosome-positive leukemiasN Engl J Med2012367207520881:CAS:528:DC%2BC38XhslyltrvJ10.1056/nejmoa1205127231902213777383 – reference: MarosticaESukbuntherngJLouryDDe JongJDe TrixheXWVermeulenADe NicolaoGO’BrienSByrdJCAdvaniRMcGreivyJPoggesiIPopulation pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignanciesCancer Chemother Pharmacol2015751111211:CAS:528:DC%2BC2cXhvV2gs7rL10.1007/s00280-014-2617-325381051 – reference: DiekstraMHFritschAKanefendtFSwenJJDjarMSörgelFKinzigMStelzerCSchindeleDGaulerTHauserSHoutsmaDRoesslerMMoritzBMrossKBergmannLOosterwijkEKiemeneyLAGuchelaarHJJaehdeUPopulation modeling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics, and clinical outcome in patients with sunitinib-treated cancerCPT Pharmacometrics Syst Pharmacol201766046131:CAS:528:DC%2BC2sXhtFKnu7%2FL10.1002/psp4.12210285711145613186 – reference: TiseoMAndreoliRGelsominoFMozzoniPAzzoniCBartolottiMBortesiBGoldoniMSiliniEMDe PalmaGMuttiAArdizzoniACorrelation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)Lung Cancer20148326527110.1016/j.lungcan.2013.12.00124388705 – reference: GuilhotFHughesTPCortesJDrukerBJBaccaraniMGathmannIHayesMGranvilCWangYInsermCICPoitiersCHUDe HospitalRAInsermPDeCHUPlasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity TrialHaematologica2012977317381:CAS:528:DC%2BC38Xhs1ajs77I10.3324/haematol.2011.045666223154953342976 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2015) Alectinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000ClinPharmR.pdf. Accessed 07 April 2019 – reference: Nijenhuis CM, Huitema ADR, Marchetti S, Blank C, Haanen JBAG, van Thienen JV, Rosing H, Schellens JHM, Beijnen JH (2016) The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. J Clin Pharmacol. https://doi.org/10.1002/jcph.728 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2015) Lenvima European public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/lenvima-epar-public-assessment-report_en.pdf. Accessed 13 February 2020 – reference: Klopp-SchulzeLMueller-SchoellANevenPKoolenSLMathijssenRJoergerMKloftCIntegrated data analysis of six clinical studies points toward model-informed precision dosing of tamoxifenFront Pharmacol2020111191:CAS:528:DC%2BB3cXhvVarur%2FO10.3389/fphar.2020.00283 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2012) Ponatinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 – reference: KhosravanRMotzerRJFumagalliERiniBIPopulation Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorClin Pharmacokinet201655125112691:CAS:528:DC%2BC28Xns1Sisro%3D10.1007/s40262-016-0404-5271540655526090 – reference: FlinnIWO’BrienSKahlBPatelMOkiYFossFFPorcuPJonesJBurgerJAJainNKellyVMAllenKDouglasMSweeneyJKellyPHorwitzSDuvelisib, a novel oral dual inhibitor of PI3K-d,g, is clinically active in advanced hematologic malignanciesBlood20181318778871:CAS:528:DC%2BC1cXhs12ks7rL10.1182/blood-2017-05-786566291919166033052 – reference: RibbaBHolfordNHMagniPTrocónizIGueorguievaIGirardPSarrCElishmereniMKloftCFribergLEA review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysisCPT Pharmacometrics Syst Pharmacol20143121:CAS:528:DC%2BC2cXhsFagur7L10.1038/psp.2014.12 – reference: NakaharaRSumimotoTOgataMSatoYItohHSuccessful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case reportClin Case Reports201971419142110.1002/ccr3.2191 – reference: MizutaSSawaMTsurumiHMatsumotoKMiyaoKHaraTTakahashiTSakemuraRKojimaHKohnoAObaMSMoritaSSakamotoJEmiNPlasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 studyInt J Clin Oncol2018239809881:CAS:528:DC%2BC1cXhtVamurrP10.1007/s10147-018-1300-9298454776154123 – reference: GroenlandSLvan EerdenRAGVerheijenRBKoolenSLWMoesDJARDesarIMEReynersAKLGelderblomHJvan ErpNPMathijssenRHJHuitemaADRSteeghsNTherapeutic drug monitoring of oral anticancer drugs: the Dutch Pharmacology Oncology Group–Therapeutic Drug Monitoring Protocol for a Prospective StudyTher Drug Monit 412019 – reference: FoxPBalleineRLLeeCGaoBBalakrishnarBMenziesAMYeapSHAliSSGebskiVProvanPCoulterSLiddleCHuiRKeffordRLynchJWongMWilckenNGurneyHDose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring—the TADE studyClin Cancer Res201622316431711:CAS:528:DC%2BC28XhtVyiurjP10.1158/1078-0432.ccr-15-147026847054 – reference: NodaSOtsujiTBabaMYoshidaTKageyamaSOkamotoKOkadaYKawauchiAOnishiHHiraDMoritaSYTeradaTAssessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients with Renal Cell CarcinomaClin Genitourin Cancer20151335035810.1016/j.clgc.2015.01.00725701374 – reference: HoukBEBelloCLPolandBRosenLSDemetriGDMotzerRJRelationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysisCancer Chemother Pharmacol2010663573711:CAS:528:DC%2BC3cXmt1als74%3D10.1007/s00280-009-1170-y19967539 – reference: Endo-TsukudeCSasakiJSaekiSIwamotoNInabaMUshijimaSKishiHFujiiSSembaHKashiwabaraKTsubataYHayashiMKaiYSaitoHIsobeTKohrogiHHamadaAPopulation Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and TransportersBiol Pharm Bull20184147561:CAS:528:DC%2BC1cXhslOnsbjK10.1248/bpb.b17-0052129311482 – reference: NijenhuisCMHuitemaADRBlankCHaanenJBAGvan ThienenJVRosingHSchellensJHMBeijnenJHClinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma PatientsJ Clin Pharmacol2017571251281:CAS:528:DC%2BC28XitFKrsr3N10.1002/jcph.78827365214 – reference: MorcosPNNueeschEJaminionFGueriniEHsuJCBordognaWBalasBMercierFExposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancerCancer Chemother Pharmacol2018821291381:CAS:528:DC%2BC1cXpsVWntbg%3D10.1007/s00280-018-3597-5297488476010493 – reference: DaryaniVMSharmaSXingGSilvermanJAdewoyeAHMathiasAExposure-response of idelalisib administered in combination with bendamustine and rituximab for the treatment of relapsed chronic lymphocytic leukemiBlood20171305344 LP5345344 – reference: KhalajZBaratiehZNikpourPSchwabMSchaeffelerEMokarianFKhanahmadHSalehiRMürdterTESalehiMClinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its MetabolitesFront Pharmacol2019101131:CAS:528:DC%2BB3cXktFOnt7c%3D10.3389/fphar.2019.00530 – reference: SinnollareddyMGCottaMORobertsJAPulciniCErgönülÖCanFBeovicBPharmacokinetic and pharmacodynamic tools to increase efficacyAntimicrobial stewardship20171AmsterdamElsevier Inc859810.1016/B978-0-12-810477-4.00007-6 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2018) NDA/BLA multi-disciplinary review and evaluation NDA 211651 TALZENNA (talazoparib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf. Accessed 14 February 2020 – reference: LimCKWeiYFTsaiMSChenKYShihJYYuCJTreatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?Eur J Cancer201810332401:CAS:528:DC%2BC1cXhs1eitrrI10.1016/j.ejca.2018.07.12830199768 – reference: LuJFEpplerSMWolfJHamiltonMRakhitABrunoRLumBLClinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancerClin Pharmacol Ther2006801361451:CAS:528:DC%2BD28XotFKhtr8%3D10.1016/j.clpt.2006.04.00716890575 – reference: GottaVWidmerNDecosterdLAChalandonYHeimDGregorMBenzRLeoncini-FransciniLBaerlocherGMDuchosalMACsajkaCBuclinTClinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trialCancer Chemother Pharmacol201474130713191:CAS:528:DC%2BC2cXhslGgtb3E10.1007/s00280-014-2599-125297989 – reference: Van VeggelMWestermanEHambergPClinical Pharmacokinetics and Pharmacodynamics of PanobinostatClin Pharmacokinet20185721291:CAS:528:DC%2BC2sXhtFCrsrnI10.1007/s40262-017-0565-x28667459 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2019) NDA Multi-Disciplinary Review and Evaluation. NDA 212327 Inrebic (fedratinib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf. Accessed 13 February 2020 – reference: ShimadaMOkawaHKondoYMaejimaTKataokaYHisamichiKMaekawaMMatsuuraMJinYMoriMSuzukiHShimosegawaTManoNMonitoring serum levels of sorafenib and its N-oxide is essential for long-term sorafenib treatment of patients with hepatocellular carcinomaTohoku J Exp Med20152371731821:CAS:528:DC%2BC28XhtFelt7fM10.1620/tjem.237.17326477611 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2018) NDA Multi-disciplinary Review and Evaluation NDA 210868 Lorlatinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210868Orig1s000MultidisciplineR.pdf. Accessed 14 February 2020 – reference: CabelLBlanchetBThomas-SchoemannAHuillardOBellesoeurACessotAGirouxJBoudou-RouquettePCoriatRVidalMSaiduNEBGolmardLAlexandreJGoldwasserFDrug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French studyFundam Clin Pharmacol201832981071:CAS:528:DC%2BC2sXhslylsbzM10.1111/fcp.1232729055166 – reference: HerbrinkMNuijenBSchellensJHMBeijnenJHHigh-tech drugs in creaky formulationsPharm Res201734175117531:CAS:528:DC%2BC2sXovVSns7s%3D10.1007/s11095-017-2185-428560695 – reference: Food and Drug Administration. Center for Drug Evaluation and Research. (2008) Bicalutamide clinical pharmacology and biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022310s000_ClinPharmR.pdf. Accessed 14 February 2020 – reference: ZhaoYYLiSZhangYZhaoHYLiaoHGuoYShiYXJiangWXueCZhangLThe relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinibMed Oncol2011286977021:CAS:528:DC%2BC3MXhtVWqtLrN10.1007/s12032-010-9541-020458561 – reference: BrownKComisarCWitjesHMaringwaJde GreefRVishwanathanKCantariniMCoxEPopulation pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancerBr J Clin Pharmacol201783121612261:CAS:528:DC%2BC2sXnsFCns78%3D10.1111/bcp.13223280094385427226 – reference: OuelletDKassirNChiuJMouksassiMSLeonowensCCoxDDeMariniDJGardnerOCristWPatelKPopulation pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanomaCancer Chemother Pharmacol2016778078171:CAS:528:DC%2BC28XktVekurk%3D10.1007/s00280-016-2993-y26940938 – reference: ZhouDLiJBuiKLearoydMBergesAMilenkovaTAl-HunitiNTomkinsonHXuHBridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology PatientsClin Pharmacokinet2019586156251:CAS:528:DC%2BC1cXitVSjtLfP10.1007/s40262-018-0714-x30357650 – reference: KurataYMiyauchiNSunoMItoTSendoTKiuraKCorrelation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancerJ Pharm Heal Care Sci20151810.1186/s40780-014-0008-x – reference: OgasawaraKZhouSKrishnaGPalmisanoMLiYPopulation pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemiaCancer Chemother Pharmacol2019848918981:CAS:528:DC%2BC1MXhs1Gksr3N10.1007/s00280-019-03929-9314446176768916 – reference: WangYYinOQPGrafPKisickiJCSchranHGreenKDose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitusJ Clin Pharmacol2008487637751:CAS:528:DC%2BD1cXns1KitLs%3D10.1177/009127000831800618508951 – reference: WangYChiaYLNedelmanJSchranHMahonFXMolimardMA therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling timesTher Drug Monit2009315795841:CAS:528:DC%2BD1MXhtFOhsbbF10.1097/ftd.0b013e3181b2c8cf19730279 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2019) Talzenna European public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/talzenna-epar-public-assessment-report_en.pdf. Accessed 14 February 2020 – reference: Food and Drug Administration. Center for Drug Evaluation and Research. (2014) Idelalisib clinical pharmacology and biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206545Orig1s000ClinPharmR.pdf. Accessed 14 February 2020 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2019) Glivec European public assessment report. https://www.ema.europa.eu/documents/product-information/glivec-epar-product-information_en.pdf. – reference: IshidaYMuraiKYamaguchiKMiyagishimaTShindoMOgawaKNagashimaTSatoSWatanabeRYamamotoSHiroseTSaitouSYonezumiMKondoTKatoYMochizukiNOhnoKKishinoSKuboKOyakeTItoSPharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemiaEur J Clin Pharmacol2016721851931:CAS:528:DC%2BC2MXhslCqtrfF10.1007/s00228-015-1968-y26507546 – reference: MinamiHKawadaKEbiHKitagawaKKimYI1ArakiKMukaiHTaharaMNakajimaHNakajimaKPhase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumorsCancer Sci200899149214981:CAS:528:DC%2BD1cXot1eitb4%3D10.1111/j.1349-7006.2008.00837.x18477034 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2017) NDA Multi-Disciplinary Review and Evaluation NDA 209606 IDHIFA (enasidenib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000MultidisciplineR.pdf. Accessed 06 April 2020 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2018) Rubraca European public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/rubraca-epar-public-assessment-report_en.pdf. – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2015) Ceritinib European Public Assessment report. https://www.ema.europa.eu/en/documents/assessment-report/zykadia-epar-public-assessment-report_en.pdf. Accessed 13 February 2020 – reference: GuptaNYangHHanleyMJZhangSLiuRKumarSRichardsonPGSkacelTVenkatakrishnanKDose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based AnalysesTarget Oncol20171264365410.1007/s11523-017-0524-3288033515610674 – reference: van ErpNPGelderblomHGuchelaarHJClinical pharmacokinetics of tyrosine kinase inhibitorsCancer Treat Rev2009356927061:CAS:528:DC%2BD1MXhsVGlsb3F10.1016/j.ctrv.2009.08.00419733976 – reference: ZhouDLiJLearoydMBuiKBergesAMilenkovaTAl-HunitiNTomkinsonHXuHEfficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology PatientsClin Pharmacol Ther2019105149215001:CAS:528:DC%2BC1MXpsFWiurw%3D10.1002/cpt.133830585620 – reference: GuptaNLabotkaRLiuGHuiAMVenkatakrishnanKExposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance studyInvestig New Drugs2016343383461:CAS:528:DC%2BC28XlvV2hsbo%3D10.1007/s10637-016-0346-7 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2018) NDA multi-disciplinary review and evaluation NDA 211155 COPIKTRA (duvelisib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf. Accessed 13 February 2020 – reference: De JongeMEHuitemaADRSchellensJHMRodenhuisSBeijnenJHIndividualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A reviewClin Pharmacokinet20054414717310.2165/00003088-200544020-0000215656695 – reference: NakaoKKobuchiSMarutaniSIwazakiATamiyaAIsaSOkishioKKanazuMTamiyaMHirashimaTImaiKSakaedaTAtagiSPopulation pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancerSci Rep201991111:CAS:528:DC%2BC1MXitlejtrvI10.1038/s41598-019-54804-9 – reference: ZhangMXuCRShamiyehELiuFYinJYVon MoltkeLLSmithWBA randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteersJ Clin Pharmacol2014544154211:CAS:528:DC%2BC2cXhs1ynsbnN10.1002/jcph.21824165976 – reference: LarsonRAYinOQPHochhausASaglioGClarkRENakamaeHGallagherNJDemirhanEHughesTPKantarjianHMLe CoutrePDPopulation pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phaseEur J Clin Pharmacol2012687237331:CAS:528:DC%2BC38XmtFaqsbo%3D10.1007/s00228-011-1200-722207416 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2018) NDA Multi-Disciplinary Review and Evaluation NDA 210498 MEKTOVITM (binimetinib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf. Accessed 13 February 2020 – reference: AbbasRHsyuPHClinical Pharmacokinetics and Pharmacodynamics of BosutinibClin Pharmacokinet201655119112041:CAS:528:DC%2BC28XmslSrtb0%3D10.1007/s40262-016-0391-627113346 – reference: WelzenMEBDezentjéVOvan SchaikRHNColbersAPHGuchelaarH-Jvan ErpNPden HartighJBurgerDMvan LaarhovenHWMThe Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 ActivityTher Drug Monit2015375015071:CAS:528:DC%2BC2MXht1WrtrrF10.1097/ftd.000000000000019526192892 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2006) Vorinostat clinical pharmacology and biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf. Accessed 01 April 2020 – reference: SavelievaMWooMMSchranHMuSNedelmanJCapdevilleRPopulation pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumorsEur J Clin Pharmacol2015716636721:CAS:528:DC%2BC2MXotlWmtrY%3D10.1007/s00228-015-1846-7259397074430599 – reference: HerbrinkMde VriesNRosingHHuitemaADRNuijenBSchellensJHMBeijnenJHDevelopment and validation of a liquid chromatography–tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugsBiomed Chromatogr201832191:CAS:528:DC%2BC2sXhvF2ksLrF10.1002/bmc.4147 – reference: Food and Drug Administration. Center for Drug Evaluation and Research. (2015) Cobimetinib clinical pharmacology and biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206192Orig1s000ClinPharmR.pdf. Accessed 12 February 2020 – reference: ProttiMMandrioliRMercoliniLTutorial: Volumetric absorptive microsampling (VAMS)Anal Chim Acta2019104632471:CAS:528:DC%2BC1cXhslWitr3E10.1016/j.aca.2018.09.00430482302 – reference: ShawATFelipEBauerTMBesseBNavarroAPostel-VinaySGainorJFJohnsonMDietrichJJamesLPClancyJSChenJMartiniJFAbbattistaASolomonBJLorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialLancet Oncol201718159015991:CAS:528:DC%2BC2sXhslSgu7vF10.1016/s1470-2045(17)30680-057772335777233 – reference: Liefaard L, Chen C (2015) Quantifying the effectiveness of dose individualization by simulation for a drug with moderate pharmacokinetic variability. Ther Drug Monit 37 – reference: AbrantesJAJönssonSKarlssonMONielsenEIHandling interoccasion variability in model-based dose individualization using therapeutic drug monitoring dataBr J Clin Pharmacol201985132613361:CAS:528:DC%2BC1MXhtVCjtr7L10.1111/bcp.13901307672546533430 – reference: YinOWangYLanzaCSchimanskyTBalezSSchranHFStoneRMPharmacokinetics (PK) and pharmacodynamics (PD) of midostaurin (PKC412) in patients with acute myeloid leukemia (AML)J Clin Oncol200826706410.1200/jco.2008.26.15_suppl.7064 – reference: GandhiLBahledaRTolaneySMKwakELClearyJMPandyaSSHollebecqueAAbbasRAnanthakrishnanRBerkenblitAKrygowskiMLiangYTurnbullKWShapiroGISoriaJCPhase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumorsJ Clin Oncol20143268751:CAS:528:DC%2BC2cXivVeisb8%3D10.1200/jco.2012.47.278724323026 – reference: SuzukiTSukawaYImamuraCKMasuishiTSatakeHKumekawaYFunakoshiSKotakaMHorieYKawaiSOkudaHTerazawaTKondohCKatoKYoshimuraKIshikawaHHamamotoYBokuNTakaishiHKanaiTA Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)Clin Colorectal Cancer2020191321.e310.1016/j.clcc.2019.10.00431732439 – reference: Food and Drug Administration. Center for Drug Evaluation and Research. (2011) Vandetanib clinical pharmacology and biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2011) Crizotinib Clinical Pharmacology and Biopharmaceutics Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf. Accessed 25 Mar 2019 – reference: SunWO’DwyerPJFinnRSRuiz-GarciaAShapiroGISchwartzGKDeMicheleAWangDCharacterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation ApproachJ Clin Pharmacol201757115911731:CAS:528:DC%2BC2sXhtlemt73J10.1002/jcph.90228419480 – reference: JonesAKFreiseKJAgarwalSKHumerickhouseRAWongSLSalemAHClinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients: a pooled population pharmacokinetic analysisAAPS J201618119212021:CAS:528:DC%2BC28XovFWhsLo%3D10.1208/s12248-016-9927-927233802 – reference: HanKJinJYMarchandMEpplerSChoongNHackSPTikooNBrunoRDresserMMusibLBudhaNRPopulation pharmacokinetics and dosing implications for cobimetinib in patients with solid tumorsCancer Chemother Pharmacol2015769179241:CAS:528:DC%2BC2MXhsFagtbfK10.1007/s00280-015-2862-026365290 – reference: Groenland SL, Geel DR, Janssen JM, de Vries N, Rosing H, Beijnen JH, Burgers JA, Smit EF, Huitema ADR, Steeghs N (2020) Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.1989 – reference: Food and Drug Administration. Center for Drug Evaluation and Research. (2012) Enzalutamide clinical pharmacology and biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000ClinPharmR.pdf. Accessed 12 February 2020 – reference: Pistilli B, Paci A, Ferreira AR, Di Meglio A, Poinsignon V, Bardet A, Menvielle G, Dumas A, Pinto S, Dauchy S, Fasse L, Cottu PH, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Jouannaud C, Levy C, Everhard S, Arveux P, Martin AL, Dima A, Lin NU, Partridge AH, Delaloge S, Michiels S, André F, Vaz-Luis I (2020) Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. J Clin Oncol. https://doi.org/10.1200/jco.19.01758 – reference: KramkimelNThomas-SchoemannASakjiLGolmardJLNoeGRegnier-RosencherEChapuisNMaubecEVidalMAvrilMFGoldwasserFMortierLDupinNBlanchetBVemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanomaTarget Oncol20161159691:STN:280:DC%2BC28%2Fmt12nsw%3D%3D10.1007/s11523-015-0375-826208946 – reference: SaltzsteinDSieberPMorrisTGalloJPrevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozoleProstate Cancer Prostatic Dis2005875831:CAS:528:DC%2BD2MXisVShsrg%3D10.1038/sj.pcan.450078215685254 – reference: WichaSGKeesMGSolmsAMinichmayrIKKratzerAKloftCTDMx: a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routineInt J Antimicrob Agents2015454424441:CAS:528:DC%2BC2MXotVGisQ%3D%3D10.1016/j.ijantimicag.2014.12.01025631677 – reference: van BrummelenEMJHuitemaADRvan WerkhovenEBeijnenJHSchellensJHMThe performance of model-based versus rule-based phase I clinical trials in oncology: a quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 yearsJ Pharmacokinet Pharmacodyn2016432352421:CAS:528:DC%2BC28XksVyhu7o%3D10.1007/s10928-016-9466-026960536 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (1997) Letrozole Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20726_FEMARA2.5MG_BIOPHARMR.PDF. Accessed 14 February 2020 – reference: LacySAMilesDNguyenLClinical pharmacokinetics and pharmacodynamics of cabozantinibClin Pharmacokinet20175647749110.1007/s40262-016-0461-927734291 – reference: VerheijenRBBinsSMathijssenRHJLolkemaMPvan DoornLSchellensJHMBeijnenJHLangenbergMHGHuitemaADRSteeghsNIndividualized pazopanib dosing: a prospective feasibility study in cancer patientsClin Cancer Res201622573857461:CAS:528:DC%2BC28XitVegt7rP10.1158/1078-0432.ccr-16-125527470967 – reference: Wang J, Zhang Z-Y, Mirza MR, Gilbert L, Fabbro M, Tinker AV, Wang X, Redondo A, Berek JS, Woelber L, Pentikis HS, Moore KN, Lorusso D, Benigno B, Hazard SJ, Follana P, Rimel BJ, Matulonis UA, Agarwal S, Kansra V (2017) 933PDThe exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial. Ann Oncol 28. https://doi.org/10.1093/annonc/mdx372.003 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2016) NDA/BLA multi-disciplinary review and evaluation NDA 209115 Rubraca (rucaparib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209115Orig1s000MultiDisciplineR.pdf. Accessed 13 February 2020 – reference: Food and Drug Administration. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Pediatric study plans: content of and process for submitting initial pediatric study plans and amended initial pediatric study plans guidance for industry. Accessed 23 March 2020 – reference: OuelletDGibianskyELeonowensCO’HaganAHaneyPSwitzkyJGoodmanVLPopulation pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolitesJ Clin Pharmacol2014546967061:CAS:528:DC%2BC2cXhtFOlt7nF10.1002/jcph.26324408395 – reference: SternbergCNDonskovFHaasNBDoehnCRussoPElmeliegyMBaneyxGBanerjeeHAimonePMotzerRJPazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinomaClin Cancer Res201824300530131:CAS:528:DC%2BC1cXht1alurnM10.1158/1078-0432.ccr-17-2652293302046748622 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2017) Rydapt European public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/rydapt-epar-public-assessment-report_en.pdf. Accessed 14 February 2020 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2012) Inlyta European public assessment report. https://www.ema.europa.eu/documents/product-information/inlyta-epar-product-information_en.pdf. Accessed 17 June 2019 – reference: Pérez-RuixoCPérez-BlancoJSChienCYuMOuelletDPérez-RuixoJJAckaertOPopulation Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer SubjectsClin Pharmacokinet2019592292441:CAS:528:DC%2BC1MXhs1elur3J10.1007/s40262-019-00808-7 – reference: Groenland SL, van Eerden RAG, Verheijen RB, de Vries N, Thijssen B, Rosing H, Beijnen JH, Koolen SLW, Mathijssen RHJ, Huitema ADR, Steeghs N (2020) Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients. Clin Pharmacokinet. https://doi.org/10.1007/s40262-020-00863-5 – reference: JainLWooSGardnerERDahutWLKohnECKummarSMouldDRGiacconeGYarchoanRVenitzJFiggWDPopulation pharmacokinetic analysis of sorafenib in patients with solid tumoursBr J Clin Pharmacol2011722943051:CAS:528:DC%2BC3MXhtV2qtrvI10.1111/j.1365-2125.2011.03963.x213920743162659 – reference: Groenland SL, van Nuland M, Bergman AM, de Feijter JM, Dezentje VO, Rosing H, Beijnen JH, Huitema ADR, Steeghs N (2020) Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. Eur J Cancer 130:32–38. https://doi.org/10.1016/j.ejca.2020.02.012 – reference: RousseauAMarquetPApplication of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugsFundam Clin Pharmacol2002162532621:CAS:528:DC%2BD38XotFGqsb8%3D10.1046/j.1472-8206.2002.00086.x12570013 – reference: RiniBIMelicharBUedaTGrünwaldVFishmanMNArranzJABairAHPithavalaYKAndrewsGIPavlovDKimSJonaschEAxitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trialLancet Oncol201314123312421:CAS:528:DC%2BC3sXhslWlsbjK10.1016/s1470-2045(13)70464-9241401844120767 – reference: GuptaAJarzabBCapdevilaJShumakerRHusseinZPopulation pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancerBr J Clin Pharmacol201681112411331:CAS:528:DC%2BC28Xot1Olsrw%3D10.1111/bcp.12907268795944876185 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2014) Palbociclib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103Orig1s000ClinPharmR.pdf. Accessed 12 February 2020 – reference: van Nuland M, Groenland SL, Bergman AM, Steeghs N, Rosing H, Venekamp N, Huitema ADR, Beijnen JH (2019) Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. Prostate cancer Prostatic Dis https://doi.org/10.1038/s41391-019-0179-5 – reference: Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI (2005) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16:1391–1397. https://doi.org/10.1093/annonc/mdi247 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2019) NDA/BLA Multi‐Disciplinary Review and Evaluation NDA 212018 BALVERSA (erdafitinib). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf. Accessed 06 April 2020 – reference: HidalgoMSiuLLNemunaitisJRizzoJHammondLATakimotoCEckhardtSGTolcherABrittenCDDenisLFerranteKVon HoffDDSilbermanSRowinskyEKPhase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesJ Clin Oncol200119326732791:CAS:528:DC%2BD3MXltlShtbs%3D10.1200/jco.2001.19.13.326711432895 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2018) Nerlynx European public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/nerlynx-epar-public-assessment-report_en.pdf. Accessed 14 February 2020 – reference: FreiwaldMSchmidUFleuryAWindSStopferPStaabAPopulation pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumorsCancer Chemother Pharmacol2014737597701:CAS:528:DC%2BC2cXis1Sjsrk%3D10.1007/s00280-014-2403-224522402 – reference: HsyuP-HMouldDRAbbasRAmanteaMPopulation Pharmacokinetic and Pharmacodynamic Analysis of BosutinibDrug Metab Pharmacokinet20142944144810.2133/dmpk.dmpk-13-rg-12624919837 – reference: SchmidUHeinzKAngeleLClaudiaFFreiwaldMPopulation pharmacokinetics of nintedanib , an inhibitor of tyrosine kinases , in patients with non-small cell lung cancer or idiopathic pulmonary fibrosisCancer Chemother Pharmacol201881891011:CAS:528:DC%2BC2sXhsl2jtr7F10.1007/s00280-017-3452-029119292 – reference: FaivreSDelbaldoCVeraKRobertCLozahicSLassauNBelloCDeprimoSBregaNMassiminiGArmandJPScigallaPRaymondESafety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancerJ Clin Oncol20062425351:CAS:528:DC%2BD28Xot1ChtQ%3D%3D10.1200/jco.2005.02.219416314617 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2015) Osimertinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 – reference: JosephsDHFisherDSSpicerJFlanaganRJClinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoringTher Drug Monit2013355625871:CAS:528:DC%2BC3sXhsFSmsL7E10.1097/ftd.0b013e318292b93124052062 – reference: DeppenweilerMFalkowskiSSaint-MarcouxFMonchaudCPicardNLarocheMLTubiana-MathieuNVenat-BouvetLMarquetPWoillardJBTowards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationshipPharmacol Res20171211381441:CAS:528:DC%2BC2sXnsFenurc%3D10.1016/j.phrs.2017.04.02928473246 – reference: TakahashiNAbumiyaMMiuraMNiiokaTSawadaKTagawaHKameokaYFujishimaNInfluence of UGT1A1 *6, *27, and *28 Polymorphisms on Nilotinib-induced Hyperbilirubinemia in Japanese Patients with Chronic Myeloid LeukemiaDrug Metab Pharmacokinet20142944945410.2133/dmpk.dmpk-14-rg-03124898899 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2019) NDA multi-disciplinary review and evaluation NDA 212099 NUBEQA (darolutamide). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212099Orig1s000MultidisciplineR.pdf. Accessed 06 April 2020 – reference: WangXRoyAHochhausAKantarjianHMChenTTShahNPDifferential effects of dosing regimen on the safety and efficacy of dasatinib:Retrospective exposure-response analysis of a phase III studyClin Pharmacol Adv Appl2013585971:CAS:528:DC%2BC3sXhtVWksbbP10.2147/cpaa.s42796 – reference: OkamotoIKanedaHSatohTOkamotoWMiyazakiMMorinagaRUedaSTerashimaMTsuyaASarashinaAKonishiKAraoTNishioKKaiserRNakagawaKPhase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumorsMol Cancer Ther20109282528331:CAS:528:DC%2BC3cXht1KhtrnJ10.1158/1535-7163.mct-10-037920688946 – reference: Groenland SL, Mathijssen RHJ, Beijnen JH, Huitema ADR, Steeghs N (2019) Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-019-02704-2 – reference: BarginearMFJaremkoMPeterIYuCKasaiYKemenyMRaptisGDesnickRJIncreasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: Effect on active metabolite isomers and the antiestrogenic activity scoreClin Pharmacol Ther2011906056111:CAS:528:DC%2BC3MXht1WqtbnI10.1038/clpt.2011.15321900890 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2018) NDA/BLA Multi-Disciplinary Review and Evaluation NDA 210951 Erleada (apalutamide). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210951Orig1s000MultidisciplineR.pdf. Accessed 13 February 2020 – reference: LacySNielsenJYangBMilesDNguyenLHutmacherMPopulation exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinomaCancer Chemother Pharmacol201881106110701:CAS:528:DC%2BC1cXnvFCmtr8%3D10.1007/s00280-018-3579-7296670665973957 – reference: Kichenadasse G, Hughes JH, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ (2019) Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-019-04002-1 – reference: MuSKurodaYShibayamaHHinoMTajimaTCorradoCLinRWaldronEBinlichFSuzukiKPanobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myelomaEur J Clin Pharmacol2016721531611:CAS:528:DC%2BC2MXhslCqtrrN10.1007/s00228-015-1967-z26494130 – reference: Food and Drug Administration. Center for Drug Evaluation and Research (2013) Ibrutinib Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205552Orig1s000ClinPharmR.pdf. Accessed 13 February 2020 – reference: HertzDLKidwellKMSeewaldNJGerschCLDestaZFlockhartDAStornioloAMStearnsVSkaarTCHayesDFHenryNLRaeJMPolymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancerPharmacogenomics J2017175215271:CAS:528:DC%2BC28XhtlyqsbfI10.1038/tpj.2016.6027549341 – reference: HeathEIChioreanEGSweeneyCJHodgeJPLagerJJFormanKMalburgLArumughamTDarMMSuttleABGainerSDLorussoPA phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumorsClin Pharmacol Ther2010888188231:CAS:528:DC%2BC3cXhsVegu7bE10.1038/clpt.2010.19920980999 – reference: Mueller-Schoell A, Klopp-schulze L, Schroth W, Michelet R, Brauch H, Huisinga W, Joerger M, Neven P, Koolen SLW, Mathijssen RHJ, Copson E, Eccles D, Chen S, Chowbay B, Tfayli A, Zgheib NK, Schwab M, Kloft C (2020) Obesity alters endoxifen plasma levels in young breast cancer patients: A pharmacometric simulation approach. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.1960 – reference: SharmaSGuoYJinFLiXDubowyRLNewcombTRamanathanSExposure-response of idelalisib administered in combination with ofatumumab for the treatment of relapsed chronic lymphocytic leukemiaBlood20151264172 LP417417210.1182/blood.V126.23.4172.4172 – reference: Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (2012) Zelboraf European public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/zelboraf-epar-public-assessment-report_en.pdf. Accessed 24 March 2020 – reference: GoldwirtLChamiIFeugeasJPPagesCBrunet-PossentiFAllayousCBaroudjianBMadelaineISauvageonHMourahSLebbéCReply to “plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance” by Funck-Brentano et alAnn Oncol2016273633641:STN:280:DC%2BC28vislGiug%3D%3D10.1093/annonc/mdv53826578723 – reference: SuttleABBallHAMolimardMHutsonTECarpenterCRajagopalanDLinYSwannSAmadoRPanditeLRelationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinomaBr J Cancer2014111190919161:CAS:528:DC%2BC2cXhvVGisLfF10.1038/bjc.2014.503253499684229638 – reference: FlahertyKTRobertCHerseyPNathanPGarbeCMilhemMDemidovLVHasselJCRutkowskiPMohrPDummerRTrefzerULarkinJMGUtikalJDrenoBNyakasMMiddletonMRBeckerJCCaseyMShermanLJWuFSOuelletDMartinA-MPatelKSchadendorfDImproved Survival with MEK Inhibition in BRAF-Mutated MelanomaN Engl J Med20123671071141:CAS:528:DC%2BC38XhtFKjs7zN10.1056/nejmoa120342122663011 – reference: SzmulewitzRZPeerCIbraheemAMartinezEKozloffMFCarthonBDonald HarveyRFishkinPYongWPChiongENabhanCKarrisonTFiggWDStadlerWMRatainMJProspective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate CancerJ Clin Oncol201836138913951:CAS:528:DC%2BC1MXhtlCit7o%3D10.1200/jco.2017.76.4381295900075941614 – reference: VelgheSStoveCPVolumetric absorptive microsampling as an alternative tool for therapeutic drug monitoring of first-generation anti-epileptic drugs (Analytical and Bioanalytical Chemistry, (2018), 410, 9, (2331-2341), 10.1007/s00216-018-0866-4)Anal Bioanal Chem201841024491:CAS:528:DC%2BC1cXjtVWlurg%3D10.1007/s00216-018-0951-829450574 – reference: Boudou-RouquettePRopertSMirOCoriatRBillemontBTodMCabanesLFranckNBlanchetBGoldwasserFVariability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysisOncologist2012171204121210.1634/theoncologist.2011-0439227520673448414 – reference: SoulieresDSenzerNNVokesEEHidalgoMAgarvalaSSSiuLLMulticenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neckJ Clin Oncol20042277851:CAS:528:DC%2BD2cXpsVKiurk%3D10.1200/jco.2004.06.07514701768 – volume: 29 start-page: 449 year: 2014 ident: 3014_CR142 publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.dmpk-14-rg-031 – volume: 36 start-page: 39 year: 2019 ident: 3014_CR198 publication-title: Med Oncol doi: 10.1007/s12032-019-1263-3 – volume: 45 start-page: 442 year: 2015 ident: 3014_CR16 publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2014.12.010 – volume: 90 start-page: 693 year: 2011 ident: 3014_CR138 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2011.174 – volume: 13 start-page: 4495 year: 2007 ident: 3014_CR271 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.ccr-07-0004 – ident: 3014_CR7 doi: 10.1007/s00228-019-02704-2 – ident: 3014_CR24 doi: 10.1097/FTD.0000000000000194 – volume: 27 start-page: 3141 year: 2009 ident: 3014_CR46 publication-title: J Clin Oncol doi: 10.1200/jco.2008.20.4818 – volume: 84 start-page: 1575 year: 2018 ident: 3014_CR109 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13591 – volume: 26 start-page: 1372 year: 2015 ident: 3014_CR105 publication-title: Ann Oncol doi: 10.1093/annonc/mdv103 – volume: 8 start-page: 75 year: 2005 ident: 3014_CR255 publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/sj.pcan.4500782 – ident: 3014_CR219 – ident: 3014_CR265 doi: 10.1111/j.1365-2125.2005.02335.x – volume: 56 start-page: 1355 year: 2017 ident: 3014_CR194 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-017-0526-4 – volume: 36 start-page: 1389 year: 2018 ident: 3014_CR100 publication-title: J Clin Oncol doi: 10.1200/jco.2017.76.4381 – volume: 32 start-page: 68 year: 2014 ident: 3014_CR208 publication-title: J Clin Oncol doi: 10.1200/jco.2012.47.2787 – ident: 3014_CR248 – volume: 29 start-page: 441 year: 2014 ident: 3014_CR162 publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.dmpk-13-rg-126 – volume: 85 start-page: 1326 year: 2019 ident: 3014_CR34 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13901 – volume: 10 start-page: 1 year: 2019 ident: 3014_CR91 publication-title: Front Pharmacol doi: 10.3389/fphar.2019.00530 – volume: 73 start-page: 999 year: 2014 ident: 3014_CR107 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-014-2435-7 – volume: 130 start-page: 5344 LP year: 2017 ident: 3014_CR268 publication-title: Blood – volume: 90 start-page: 605 year: 2011 ident: 3014_CR88 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2011.153 – volume: 101 start-page: 708 year: 2009 ident: 3014_CR5 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp079 – ident: 3014_CR237 – volume: 17 start-page: 521 year: 2017 ident: 3014_CR281 publication-title: Pharmacogenomics J doi: 10.1038/tpj.2016.60 – ident: 3014_CR128 – ident: 3014_CR78 doi: 10.1007/s40262-016-0443-y – volume: 22 start-page: 3164 year: 2016 ident: 3014_CR20 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.ccr-15-1470 – volume: 69 start-page: 813 year: 2013 ident: 3014_CR140 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-012-1385-4 – volume: 13 start-page: 350 year: 2015 ident: 3014_CR79 publication-title: Clin Genitourin Cancer doi: 10.1016/j.clgc.2015.01.007 – volume: 13 start-page: 207 year: 2007 ident: 3014_CR25 publication-title: J Oncol Pharm Pract doi: 10.2165/00003088-199018040-00004 – volume: 34 start-page: 338 year: 2016 ident: 3014_CR192 publication-title: Investig New Drugs doi: 10.1007/s10637-016-0346-7 – volume: 19 start-page: 13 year: 2020 ident: 3014_CR234 publication-title: Clin Colorectal Cancer doi: 10.1016/j.clcc.2019.10.004 – volume: 11 start-page: 1 year: 2020 ident: 3014_CR92 publication-title: Front Pharmacol doi: 10.3389/fphar.2020.00283 – volume: 48 start-page: 522 year: 2018 ident: 3014_CR27 publication-title: J Pharm Pract Res doi: 10.1002/jppr.1432 – ident: 3014_CR213 – volume: 23 start-page: 5305 year: 2005 ident: 3014_CR270 publication-title: J Clin Oncol doi: 10.1200/jco.2005.16.584 – volume: 53 start-page: 491 year: 2013 ident: 3014_CR101 publication-title: J Clin Pharmacol doi: 10.1002/jcph.73 – volume: 7 start-page: 1419 year: 2019 ident: 3014_CR143 publication-title: Clin Case Reports doi: 10.1002/ccr3.2191 – ident: 3014_CR261 – ident: 3014_CR175 – ident: 3014_CR181 – volume: 57 start-page: 335 year: 2018 ident: 3014_CR149 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-017-0559-8 – ident: 3014_CR232 – volume: 1106–1107 start-page: 26 year: 2019 ident: 3014_CR96 publication-title: J Chromatogr B doi: 10.1016/j.jchromb.2019.01.001 – volume: 16 start-page: 253 year: 2002 ident: 3014_CR26 publication-title: Fundam Clin Pharmacol doi: 10.1046/j.1472-8206.2002.00086.x – volume: 14 start-page: 1233 year: 2013 ident: 3014_CR106 publication-title: Lancet Oncol doi: 10.1016/s1470-2045(13)70464-9 – volume: 19 start-page: 3267 year: 2001 ident: 3014_CR131 publication-title: J Clin Oncol doi: 10.1200/jco.2001.19.13.3267 – volume: 81 start-page: 89 year: 2018 ident: 3014_CR212 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-017-3452-0 – volume: 71 start-page: 209 year: 2013 ident: 3014_CR164 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-012-1998-4 – volume: 37 start-page: 501 year: 2015 ident: 3014_CR87 publication-title: Ther Drug Monit doi: 10.1097/ftd.0000000000000195 – volume: 27 start-page: 363 year: 2016 ident: 3014_CR51 publication-title: Ann Oncol doi: 10.1093/annonc/mdv538 – volume: 59 start-page: 229 year: 2019 ident: 3014_CR158 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-019-00808-7 – volume: 33 start-page: 39 year: 1998 ident: 3014_CR254 publication-title: Eur Urol doi: 10.1159/000019526 – volume: 74 start-page: 1307 year: 2014 ident: 3014_CR18 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-014-2599-1 – volume: 6 start-page: 604 year: 2017 ident: 3014_CR82 publication-title: CPT Pharmacometrics Syst Pharmacol doi: 10.1002/psp4.12210 – ident: 3014_CR266 – volume: 55 start-page: 1251 year: 2016 ident: 3014_CR81 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-016-0404-5 – volume: 18 start-page: 1590 year: 2017 ident: 3014_CR202 publication-title: Lancet Oncol doi: 10.1016/s1470-2045(17)30680-0 – volume: 237 start-page: 173 year: 2015 ident: 3014_CR242 publication-title: Tohoku J Exp Med doi: 10.1620/tjem.237.173 – volume: 367 start-page: 107 year: 2012 ident: 3014_CR123 publication-title: N Engl J Med doi: 10.1056/nejmoa1203421 – ident: 3014_CR249 – volume: 32 start-page: 98 year: 2018 ident: 3014_CR19 publication-title: Fundam Clin Pharmacol doi: 10.1111/fcp.12327 – volume: 60 start-page: 218 year: 2020 ident: 3014_CR250 publication-title: J Clin Pharmacol doi: 10.1002/jcph.1520 – volume: 97 start-page: 731 year: 2012 ident: 3014_CR67 publication-title: Haematologica doi: 10.3324/haematol.2011.045666 – volume: 94 start-page: 652 year: 2002 ident: 3014_CR9 publication-title: CancerSpectrum Knowl Environ doi: 10.1093/jnci/94.9.652 – volume: 53 start-page: 1149 year: 2014 ident: 3014_CR99 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-014-0178-6 – ident: 3014_CR170 – volume: 31 start-page: 579 year: 2009 ident: 3014_CR10 publication-title: Ther Drug Monit doi: 10.1097/ftd.0b013e3181b2c8cf – volume: 57 start-page: 31 year: 2016 ident: 3014_CR69 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2015.12.029 – ident: 3014_CR150 – volume: 24 start-page: 3005 year: 2018 ident: 3014_CR75 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.ccr-17-2652 – volume: 15 start-page: 84 year: 2015 ident: 3014_CR84 publication-title: Pharm J doi: 10.1038/tpj.2014.34 – volume: 22 start-page: 77 year: 2004 ident: 3014_CR132 publication-title: J Clin Oncol doi: 10.1200/jco.2004.06.075 – volume: 53 start-page: 305 year: 2014 ident: 3014_CR12 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-014-0137-2 – volume: 10 start-page: 429 year: 2015 ident: 3014_CR120 publication-title: Target Oncol doi: 10.1007/s11523-014-0349-2 – ident: 3014_CR36 doi: 10.1097/ftd.0000000000000767 – volume: 81 start-page: 1124 year: 2016 ident: 3014_CR199 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12907 – volume: 57 start-page: 1159 year: 2017 ident: 3014_CR225 publication-title: J Clin Pharmacol doi: 10.1002/jcph.902 – ident: 3014_CR187 – volume: 23 start-page: 980 year: 2018 ident: 3014_CR178 publication-title: Int J Clin Oncol doi: 10.1007/s10147-018-1300-9 – ident: 3014_CR221 – volume: 102 start-page: 765 year: 2017 ident: 3014_CR13 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.787 – ident: 3014_CR103 – volume: 60 start-page: 515 year: 2020 ident: 3014_CR183 publication-title: J Clin Pharmacol doi: 10.1002/jcph.1547 – volume: 126 start-page: 4172 LP year: 2015 ident: 3014_CR267 publication-title: Blood doi: 10.1182/blood.V126.23.4172.4172 – volume: 35 start-page: 692 year: 2009 ident: 3014_CR2 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2009.08.004 – ident: 3014_CR182 – volume: 45 start-page: 707 year: 2018 ident: 3014_CR66 publication-title: J Pharmacokinet Pharmacodyn doi: 10.1007/s10928-018-9600-2 – ident: 3014_CR85 doi: 10.1002/cpt.1960 – ident: 3014_CR49 doi: 10.1002/cpt.1989 – volume: 26 start-page: 7064 year: 2008 ident: 3014_CR206 publication-title: J Clin Oncol doi: 10.1200/jco.2008.26.15_suppl.7064 – volume: 30 start-page: 442O year: 2019 ident: 3014_CR59 publication-title: Ann Oncol doi: 10.1093/annonc/mdz244.004 – ident: 3014_CR86 doi: 10.1200/jco.19.01758 – ident: 3014_CR161 – volume: 37 start-page: 251 year: 2011 ident: 3014_CR3 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2010.08.006 – ident: 3014_CR253 doi: 10.1093/annonc/mdi247 – volume: 363 start-page: 1801 year: 2010 ident: 3014_CR110 publication-title: N Engl J Med doi: 10.1056/nejmoa1001671 – volume: 14 start-page: 882 year: 2013 ident: 3014_CR214 publication-title: Lancet Oncol doi: 10.1016/s1470-2045(13)70240-7 – ident: 3014_CR209 – volume: 36 start-page: 326 year: 2014 ident: 3014_CR115 publication-title: Ther Drug Monit doi: 10.1097/ftd.0000000000000004 – ident: 3014_CR104 – ident: 3014_CR236 – volume: 62 start-page: 97 year: 2006 ident: 3014_CR70 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2006.02719.x – ident: 3014_CR259 – volume: 110 start-page: 2441 year: 2014 ident: 3014_CR47 publication-title: Br J Cancer doi: 10.1038/bjc.2014.194 – volume: 57 start-page: 21 year: 2018 ident: 3014_CR226 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-017-0565-x – volume: 104 start-page: e222 year: 2019 ident: 3014_CR275 publication-title: Haematologica doi: 10.3324/haematol.2018.213157 – volume: 18 start-page: 1192 year: 2016 ident: 3014_CR277 publication-title: AAPS J doi: 10.1208/s12248-016-9927-9 – volume: 39 start-page: 1137 year: 2019 ident: 3014_CR264 publication-title: Pharmacotherapy doi: 10.1002/phar.2339 – volume: 15 start-page: 6702 year: 2009 ident: 3014_CR282 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.ccr-09-0369 – volume: 24 start-page: 25 year: 2006 ident: 3014_CR80 publication-title: J Clin Oncol doi: 10.1200/jco.2005.02.2194 – ident: 3014_CR137 – ident: 3014_CR188 doi: 10.1002/jcph.1556 – volume: 110 start-page: 2441 year: 2014 ident: 3014_CR119 publication-title: Br J Cancer doi: 10.1038/bjc.2014.194 – ident: 3014_CR63 doi: 10.1038/s41391-019-0179-5 – volume: 22 start-page: 5722 year: 2016 ident: 3014_CR130 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.ccr-16-0536 – ident: 3014_CR126 – volume: 73 start-page: 759 year: 2014 ident: 3014_CR153 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-014-2403-2 – volume: 47 start-page: 593 year: 2017 ident: 3014_CR28 publication-title: Intern Med J doi: 10.1111/imj.13412 – ident: 3014_CR231 – volume: 50 start-page: 486 year: 2014 ident: 3014_CR64 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2013.11.022 – ident: 3014_CR14 doi: 10.1007/s40262-018-0683-0 – volume: 9 start-page: 1 year: 2019 ident: 3014_CR151 publication-title: Sci Rep doi: 10.1038/s41598-019-54804-9 – volume: 77 start-page: 807 year: 2016 ident: 3014_CR50 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-016-2993-y – volume: 48 start-page: 763 year: 2008 ident: 3014_CR203 publication-title: J Clin Pharmacol doi: 10.1177/0091270008318006 – volume: 57 start-page: 125 year: 2017 ident: 3014_CR144 publication-title: J Clin Pharmacol doi: 10.1002/jcph.788 – volume: 74 start-page: 85 year: 2014 ident: 3014_CR71 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-014-2473-1 – volume: 18 start-page: 568 year: 2012 ident: 3014_CR224 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.ccr-11-0509 – ident: 3014_CR276 – ident: 3014_CR43 doi: 10.1007/s40262-020-00863-5 – start-page: 85 volume-title: Antimicrobial stewardship year: 2017 ident: 3014_CR15 doi: 10.1016/B978-0-12-810477-4.00007-6 – volume: 472 start-page: 26 year: 2017 ident: 3014_CR174 publication-title: Clin Chim Acta doi: 10.1016/j.cca.2017.07.012 – volume: 43 start-page: 29 year: 2012 ident: 3014_CR179 publication-title: Japanese J Clin Pharmacol Ther doi: 10.3999/jscpt.43.29 – ident: 3014_CR220 – volume: 147 start-page: 288 year: 2018 ident: 3014_CR97 publication-title: J Pharm Biomed Anal doi: 10.1016/j.jpba.2017.07.029 – ident: 3014_CR154 – ident: 3014_CR77 doi: 10.1016/j.clgc.2018.12.001 – ident: 3014_CR32 doi: 10.4155/ipk-2018-0005 – ident: 3014_CR263 – ident: 3014_CR125 – ident: 3014_CR257 – ident: 3014_CR57 – ident: 3014_CR160 – ident: 3014_CR54 doi: 10.1007/s00280-019-04002-1 – volume: 23 start-page: 936 year: 2018 ident: 3014_CR121 publication-title: Int J Clin Oncol doi: 10.1007/s10147-018-1302-7 – volume: 83 start-page: 1216 year: 2017 ident: 3014_CR222 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13223 – ident: 3014_CR272 doi: 10.1007/s40262-016-0452-x – volume: 43 start-page: 235 year: 2016 ident: 3014_CR6 publication-title: J Pharmacokinet Pharmacodyn doi: 10.1007/s10928-016-9466-0 – volume: 80 start-page: 136 year: 2006 ident: 3014_CR134 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2006.04.007 – volume: 3 start-page: 12 year: 2014 ident: 3014_CR39 publication-title: CPT Pharmacometrics Syst Pharmacol doi: 10.1038/psp.2014.12 – volume: 111 start-page: 4022 year: 2008 ident: 3014_CR45 publication-title: Blood doi: 10.1182/blood-2007-10-116475 – volume: 59 start-page: 1551 year: 2019 ident: 3014_CR168 publication-title: J Clin Pharmacol doi: 10.1002/jcph.1467 – volume: 60 start-page: 35 year: 2005 ident: 3014_CR72 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2005.02372.x – volume: 38 start-page: 649 year: 2016 ident: 3014_CR93 publication-title: Ther Drug Monit doi: 10.1097/ftd.0000000000000349 – volume: 72 start-page: 153 year: 2016 ident: 3014_CR227 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-015-1967-z – volume: 49 start-page: 1109 year: 2009 ident: 3014_CR246 publication-title: J Pharm Biomed Anal doi: 10.1016/j.jpba.2009.02.008 – ident: 3014_CR74 doi: 10.1158/1078-0432.ccr-12-0490 – volume: 41 start-page: 47 year: 2018 ident: 3014_CR135 publication-title: Biol Pharm Bull doi: 10.1248/bpb.b17-00521 – volume: 410 start-page: 2449 year: 2018 ident: 3014_CR17 publication-title: Anal Bioanal Chem doi: 10.1007/s00216-018-0951-8 – volume: 76 start-page: 917 year: 2015 ident: 3014_CR258 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-015-2862-0 – volume: 53 start-page: 185 year: 2014 ident: 3014_CR243 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-013-0108-z – volume: 88 start-page: 818 year: 2010 ident: 3014_CR118 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2010.199 – volume: 109 start-page: 3496 year: 2007 ident: 3014_CR114 publication-title: Blood doi: 10.1182/blood-2006-07-036012 – ident: 3014_CR159 – volume: 72 start-page: 185 year: 2016 ident: 3014_CR177 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-015-1968-y – ident: 3014_CR216 – ident: 3014_CR274 – ident: 3014_CR165 – volume: 71 start-page: 663 year: 2015 ident: 3014_CR228 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-015-1846-7 – volume: 78 start-page: 63 year: 2016 ident: 3014_CR108 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-016-3050-6 – ident: 3014_CR148 – volume: 68 start-page: 723 year: 2012 ident: 3014_CR141 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-011-1200-7 – volume: 103 start-page: 32 year: 2018 ident: 3014_CR152 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2018.07.128 – ident: 3014_CR205 – volume: 53 start-page: 721 year: 2013 ident: 3014_CR240 publication-title: J Clin Pharmacol doi: 10.1002/jcph.102 – volume: 77 start-page: 89 year: 2016 ident: 3014_CR269 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-015-2891-8 – volume: 16 start-page: 274 year: 2015 ident: 3014_CR112 publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2014.12.004 – volume: 5 start-page: 85 year: 2013 ident: 3014_CR176 publication-title: Clin Pharmacol Adv Appl doi: 10.2147/cpaa.s42796 – volume: 131 start-page: 877 year: 2018 ident: 3014_CR260 publication-title: Blood doi: 10.1182/blood-2017-05-786566 – volume: 38 start-page: 645 year: 2015 ident: 3014_CR68 publication-title: Biol Pharm Bull doi: 10.1248/bpb.b15-00103 – volume: 28 start-page: 697 year: 2011 ident: 3014_CR4 publication-title: Med Oncol doi: 10.1007/s12032-010-9541-0 – volume: 1046 start-page: 32 year: 2019 ident: 3014_CR98 publication-title: Anal Chim Acta doi: 10.1016/j.aca.2018.09.004 – volume: 9 start-page: 887 year: 2015 ident: 3014_CR22 publication-title: Biomark Med doi: 10.2217/bmm.15.78 – volume: 44 start-page: 147 year: 2005 ident: 3014_CR29 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200544020-00002 – volume: 38 start-page: 143 year: 2016 ident: 3014_CR111 publication-title: Ther Drug Monit doi: 10.1097/ftd.0000000000000260 – ident: 3014_CR189 – ident: 3014_CR252 – volume: 72 start-page: 54 year: 2017 ident: 3014_CR62 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.11.027 – volume: 56 start-page: 477 year: 2017 ident: 3014_CR41 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-016-0461-9 – ident: 3014_CR147 – ident: 3014_CR280 – volume: 35 start-page: 562 year: 2013 ident: 3014_CR38 publication-title: Ther Drug Monit doi: 10.1097/ftd.0b013e318292b931 – volume: 100 start-page: 1728 year: 2009 ident: 3014_CR279 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2009.01237.x – volume: 143 start-page: 477 year: 2014 ident: 3014_CR122 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-013-2826-1 – volume: 105 start-page: 1492 year: 2019 ident: 3014_CR218 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.1338 – volume: 99 start-page: 32 year: 2015 ident: 3014_CR156 publication-title: Steroids doi: 10.1016/j.steroids.2014.08.007 – ident: 3014_CR204 – volume: 6 start-page: S1512 year: 2017 ident: 3014_CR30 publication-title: Transl Cancer Res doi: 10.21037/tcr.2017.09.14 – ident: 3014_CR235 – ident: 3014_CR40 doi: 10.1016/j.ejca.2020.02.012 – ident: 3014_CR58 – ident: 3014_CR195 – ident: 3014_CR210 – volume: 89 start-page: 718 year: 2011 ident: 3014_CR83 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2011.32 – volume: 111 start-page: 1909 year: 2014 ident: 3014_CR61 publication-title: Br J Cancer doi: 10.1038/bjc.2014.503 – volume: 32 start-page: 1 year: 2018 ident: 3014_CR94 publication-title: Biomed Chromatogr doi: 10.1002/bmc.4147 – volume: 17 start-page: 1204 year: 2012 ident: 3014_CR244 publication-title: Oncologist doi: 10.1634/theoncologist.2011-0439 – volume: 153 start-page: 583 year: 2015 ident: 3014_CR89 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-015-3562-5 – volume: 34 start-page: 1751 year: 2017 ident: 3014_CR37 publication-title: Pharm Res doi: 10.1007/s11095-017-2185-4 – ident: 3014_CR42 doi: 10.1002/cpt.1515 – volume: 82 start-page: 129 year: 2018 ident: 3014_CR127 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-018-3597-5 – ident: 3014_CR136 – volume: 98 start-page: 1633 year: 2008 ident: 3014_CR116 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604355 – ident: 3014_CR184 – volume: 47 start-page: 807 year: 2008 ident: 3014_CR207 publication-title: Clin Pharmacokinet doi: 10.2165/0003088-200847120-00005 – ident: 3014_CR1 – volume: 99 start-page: 1492 year: 2008 ident: 3014_CR241 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2008.00837.x – volume: 11 start-page: 1 year: 2020 ident: 3014_CR35 publication-title: Front Pharmacol doi: 10.3389/fphar.2020.00794 – volume: 103 start-page: 956 year: 2018 ident: 3014_CR23 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.937 – ident: 3014_CR238 – volume: 57 start-page: 652 year: 2017 ident: 3014_CR171 publication-title: J Clin Pharmacol doi: 10.1002/jcph.849 – volume: 54 start-page: 415 year: 2014 ident: 3014_CR185 publication-title: J Clin Pharmacol doi: 10.1002/jcph.218 – volume: 48 start-page: 887 year: 2012 ident: 3014_CR113 publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2012.03.020 – volume: 57 start-page: 1138 year: 2017 ident: 3014_CR197 publication-title: J Clin Pharmacol doi: 10.1002/jcph.917 – volume-title: Ther Drug Monit 41 year: 2019 ident: 3014_CR55 – volume: 55 start-page: 1191 year: 2016 ident: 3014_CR163 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-016-0391-6 – ident: 3014_CR173 – volume: 26 start-page: 1470 year: 2015 ident: 3014_CR52 publication-title: Ann Oncol doi: 10.1093/annonc/mdv189 – volume: 11 start-page: 59 year: 2016 ident: 3014_CR53 publication-title: Target Oncol doi: 10.1007/s11523-015-0375-8 – volume: 83 start-page: 265 year: 2014 ident: 3014_CR133 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2013.12.001 – ident: 3014_CR273 – volume: 367 start-page: 2075 year: 2012 ident: 3014_CR230 publication-title: N Engl J Med doi: 10.1056/nejmoa1205127 – ident: 3014_CR229 – volume: 22 start-page: 5738 year: 2016 ident: 3014_CR48 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.ccr-16-1255 – volume: 174 start-page: 561 year: 2019 ident: 3014_CR95 publication-title: J Pharm Biomed Anal doi: 10.1016/j.jpba.2019.06.034 – volume: 121 start-page: 138 year: 2017 ident: 3014_CR21 publication-title: Pharmacol Res doi: 10.1016/j.phrs.2017.04.029 – ident: 3014_CR56 – ident: 3014_CR124 – ident: 3014_CR233 – volume: 81 start-page: 1061 year: 2018 ident: 3014_CR166 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-018-3579-7 – volume: 12 start-page: 643 year: 2017 ident: 3014_CR193 publication-title: Target Oncol doi: 10.1007/s11523-017-0524-3 – ident: 3014_CR201 – volume: 9 start-page: 2825 year: 2010 ident: 3014_CR211 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.mct-10-0379 – volume: 66 start-page: 357 year: 2010 ident: 3014_CR60 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-009-1170-y – volume: 84 start-page: 891 year: 2019 ident: 3014_CR186 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-019-03929-9 – ident: 3014_CR278 – ident: 3014_CR169 – volume: 33 start-page: 506 year: 2015 ident: 3014_CR102 publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.7_suppl.506 – volume: 67 start-page: 1017 year: 2011 ident: 3014_CR139 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-011-1042-3 – volume: 57 start-page: 1 year: 2018 ident: 3014_CR8 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-017-0571-z – volume: 106 start-page: 250 year: 2010 ident: 3014_CR31 publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/j.1742-7843.2009.00533.x – volume: 54 start-page: 696 year: 2014 ident: 3014_CR172 publication-title: J Clin Pharmacol doi: 10.1002/jcph.263 – volume: 72 start-page: 294 year: 2011 ident: 3014_CR247 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2011.03963.x – volume: 30 start-page: 4017 year: 2012 ident: 3014_CR11 publication-title: J Clin Oncol doi: 10.1200/jco.2012.43.5362 – ident: 3014_CR145 doi: 10.1002/jcph.728 – volume: 34 start-page: 565 year: 2012 ident: 3014_CR33 publication-title: Ther Drug Monit doi: 10.1097/ftd.0b013e31826aabc3 – volume: 7 start-page: 1 year: 2012 ident: 3014_CR245 publication-title: PLoS One doi: 10.1371/journal.pone.0042875 – volume: 29 start-page: 3232 year: 2011 ident: 3014_CR90 publication-title: J Clin Oncol doi: 10.1200/jco.2010.31.4427 – ident: 3014_CR200 – volume: 58 start-page: 615 year: 2019 ident: 3014_CR217 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-018-0714-x – volume: 82 start-page: 971 year: 2018 ident: 3014_CR196 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-018-3687-4 – volume: 78 start-page: 543 year: 2014 ident: 3014_CR155 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12378 – ident: 3014_CR167 doi: 10.1007/s10928-019-09659-y – ident: 3014_CR44 doi: 10.1111/bcp.13327 – ident: 3014_CR223 – ident: 3014_CR262 – ident: 3014_CR215 doi: 10.1093/annonc/mdx372.003 – ident: 3014_CR157 – ident: 3014_CR239 – ident: 3014_CR180 – volume: 57 start-page: 637 year: 2018 ident: 3014_CR65 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-017-0582-9 – ident: 3014_CR256 – volume: 12 start-page: 6073 year: 2006 ident: 3014_CR117 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.ccr-05-2596 – volume: 80 start-page: 1171 year: 2017 ident: 3014_CR76 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-017-3463-x – ident: 3014_CR191 – ident: 3014_CR251 – volume: 1 start-page: 8 year: 2015 ident: 3014_CR129 publication-title: J Pharm Heal Care Sci doi: 10.1186/s40780-014-0008-x – ident: 3014_CR146 – volume: 75 start-page: 111 year: 2015 ident: 3014_CR190 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-014-2617-3 – volume: 56 start-page: 287 year: 2017 ident: 3014_CR73 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-016-0439-7 – reference: 33320282 - Eur J Clin Pharmacol. 2020 Dec 15;: |
| SSID | ssj0015903 |
| Score | 2.629087 |
| SecondaryResourceType | review_article |
| Snippet | Purpose
This review provides an overview of the current challenges in oral targeted antineoplastic drug (OAD) dosing and outlines the unexploited value of... This review provides an overview of the current challenges in oral targeted antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic... PurposeThis review provides an overview of the current challenges in oral targeted antineoplastic drug (OAD) dosing and outlines the unexploited value of... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 441 |
| SubjectTerms | Adverse events Antineoplastic drugs Biomedical and Life Sciences Biomedicine Dosage Dose-response effects Drug dosages Imatinib Inhibitor drugs Pharmacokinetics Pharmacology/Toxicology Review Risk factors Tamoxifen Targeted cancer therapy Therapeutic drug monitoring Toxicity |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1NT9wwEB0VeukFtZRCKK1cqeLCWiSxN45PCFVFiEPFAaS9RYk_AAl2gewe-PedcZwsC4JbJNtJPDO239jjNwC_TVa7IrUF19o3lMJM8kahs-JTZyVxmgkXoi3-FaeX8mwynsQNtzaGVfZzYpio7czQHvkhuglKUKbc8uj-gVPWKDpdjSk01uAjUZeRVavJ4HDhSp1G0t2MF1ql8dJMuDoXiF84OU_Bq-Dl6sL0Cm2-Dpp8cXIaFqSTz7ARkSQ77lT_BT646Sbsn3dU1E8jdrG8WdWO2D47X5JUP32F42fFzD4urthdGN30LTbzjC7usy5M3FlWUz4JijWv275-uwWXJ38v_pzymE6BG4Rlc-4znwuP-KRGTCRFQ89W6tSXVmgnrPJlboqsSUtvEHQUuTLos-rGOXRRSq_FN1ifzqZuB1iNoNBiW6vw1bqxCNvGonBSCOONzOoEsl6WlYlc45Ty4rYaWJKD_CuUfxXkX5UJHAxt7jumjXdr7_UqquKoa6uljSTwayjG8UKHIDWKaUF1xqUmEJgnsN1pdPicEMRFJLG1WtH1UIG4uFdLpjfXgZNb0XmyHCcw6q1i-Vtv92L3_V58h085hdCEQKE9WJ8_LtwPxEDz5mcw9P-oNgH_ priority: 102 providerName: ProQuest |
| Title | Therapeutic drug monitoring of oral targeted antineoplastic drugs |
| URI | https://link.springer.com/article/10.1007/s00228-020-03014-8 https://www.ncbi.nlm.nih.gov/pubmed/33165648 https://www.proquest.com/docview/2497365478 https://www.proquest.com/docview/2458964412 https://pubmed.ncbi.nlm.nih.gov/PMC7935845 |
| Volume | 77 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swED-W9KUvZev6kbULGoy-NAbbki3rMQnJwgYhjAbSJ2NbUlvo0tEkD_nveyc7TtOPwV4sw50s-2Sh33Gn3wF8L4LMxL6OPaVsTiXMhJdLdFasb7QgTjNuXLbFOB5Nxc9ZNKtocugszIv4PZF9hsShjE6OQ_9e0oC9KOCSyjT0434dMYiUXxHsBl6spF8dkHn7Gbub0Ctk-TpB8kWU1G0-w49wUKFG1i2n-RN8MPNDuJiUtNPrDrvanqJadNgFm2wJqdefoftMzPTj6ob9cSuZxmIPltEhfVamhBvNMqodQXnl2WKjvziC6XBw1R95VekEr0AItvRsYENuEYtkiH8Ez-leC-XbRHNluJY2CYs4yP3EFggw4lAW6J-q3Bh0RxKr-DE05w9zcwosQwCosa-W-GiVa4RoEY-N4LywhQiyFgQbW6ZFxStO5S3u05oR2dk_Rfunzv5p0oLLus_fklXjn9rnmylKqxW2SNFtlJwqJ6P4Wy3GtUEBjwzNtCKdKFEE-MIWnJQzWg_HOfEOCewtd-a6ViDe7V3J_O7W8W9Lih2LqAWdzV-xfa33v-LL_6mfwX5I6TMuSegcmsvHlfmK-GeZt6EhZ7INe91hrzem9sf1rwG2vcF48rvtlgVep2H3CTxBAQQ |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB4hOLSXir5DebhSy6VrNYm9cXKoECpFS6GIwyLtLU38aJHoLiW7Qvun-I2dcR7bLSo3bpFsx_F47PkmHn8D8E5HhU1Ck_AscyWlMJO8VOisuNAaSZxmwvpoi9NkcC6_jvqjFbht78JQWGW7J_qN2kw0_SP_iG6CEpQpN927-s0paxSdrrYpNGq1OLbzG3TZqk9HBzi_7-P48Mvw84A3WQW4RnQy5S5ysXBopguEBlKU9GxkFrrUiMwKo1wa6yQqw9RptL1JrDS6bllpLSL11BH5Em75a2h4Q3L21Khz8BAZhA3Jb8STTIXNJR1_Vc8TzXBy1rwXw9NlQ3gH3d4N0vznpNYbwMN1eNIgV7Zfq9pTWLHjZ7B7VlNfz3tsuLjJVfXYLjtbkGLPn8P-X8XMXM9-sF9-N6G-2MQxIgpgdVi6Nayg_BUU215Ubf3qBZw_iKBfwup4MravgRUobINtjcJXZ6VBmNgXiZVCaKdlVAQQtbLMdcNtTik2LvOOldnLP0f5517-eRrAh67NVc3scW_tzXaK8maVV_lCJwN42xXj-qRDlwLFNKM6_TQj0BkH8Kqe0a47IYj7SGJrtTTXXQXi_l4uGV_89Bzgis6vZT-AXqsVi8_6_yg27h_FDjwaDL-d5CdHp8dv4HFM4Ts-SGkTVqfXM7uF-GtabnulZ_D9oVfZH3niPcw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB5VWwlxQbwJLWAk6IWNmsROHB8QKrSrlqLVCrVSbyHxA5Dobml2hfav8euYcR7LUtFbb5Fsx_F4bH-TGX8D8ErHpc0ik4VKuYpSmImwkmisuMgaQZxm3Ppoi3F2eCo-nqVnG_C7uwtDYZXdnug3ajPT9I98F80EySlTbr7r2rCIyf7o3cXPkDJIkae1S6fRqMixXf5C861-e7SPc_06SUYHJx8OwzbDQKgRqcxDF7uEOzyyS4QJglf0bISKXG64stxIlyc6i6sodxrP4SyRGs04VVmLqD13RMSE2_-mJKtoAJvvD8aTz70PI1VRS_kbh5mSUXtlx1_c87QzIZlu3qYJ8_Vj8QrWvRqy-Y_f1h-Ho7twp8WxbK9RvHuwYaf3YWfSEGEvh-xkda-rHrIdNllRZC8fwN5fxcxcLr6yc7-3UF9s5hjRBrAmSN0aVlI2C4p0L-uufv0QTm9E1I9gMJ1N7RNgJUJSg22NxFeryiBoTHlmBefaaRGXAcSdLAvdMp1Two0fRc_R7OVfoPwLL_8iD-BN3-ai4fm4tvZ2N0VFu-brYqWhAbzsi3G1kgumRDEtqE6aK4KgSQCPmxntu-OcmJAEtpZrc91XICbw9ZLp92-eEVySN1ukAQw7rVh91v9H8fT6UbyAW7jCik9H4-MtuJ1QLI-PWNqGwfxyYZ8hGJtXz1utZ_DlphfaH--7Q2c |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+drug+monitoring+of+oral+targeted+antineoplastic+drugs&rft.jtitle=European+journal+of+clinical+pharmacology&rft.au=Mueller-Schoell%2C+Anna&rft.au=Groenland%2C+Stefanie+L.&rft.au=Scherf-Clavel%2C+Oliver&rft.au=van+Dyk%2C+Madel%C3%A9&rft.date=2021-04-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0031-6970&rft.eissn=1432-1041&rft.volume=77&rft.issue=4&rft.spage=441&rft.epage=464&rft_id=info:doi/10.1007%2Fs00228-020-03014-8&rft.externalDocID=10_1007_s00228_020_03014_8 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6970&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6970&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6970&client=summon |